

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office


February 09, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/429,697

FILING DATE: November 27, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/37775



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

M. Sias
M. SIAS
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

Thomas J Engellenner)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003 <small>Patent fees are subject to annual revision.</small>		Complete if Known	
<input checked="" type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27		Application Number	Not Yet Assigned
TOTAL AMOUNT OF PAYMENT (\$) 80.00		Filing Date	November 27, 2002
		First Named Inventor	Singh et al.
		Examiner Name	Not Yet Assigned
		Group Art Unit	N/A
		Attorney Docket No.	005363-3126

METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)																																																																																																																																																																																	
<input checked="" type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None <input type="checkbox"/> Deposit Account Deposit Account Number: 141449 Deposit Account Name: Nutter McClennen & Fish LLP The Commissioner is hereby authorized to: (check all that apply) <input type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments <input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account	3. ADDITIONAL FEES <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Large Entity</th> <th style="text-align: left;">Small Entity</th> <th style="text-align: left;">Fee Description</th> <th style="text-align: left;">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr><td>1051</td><td>130</td><td>2051</td><td>65</td><td>Surcharge - late filing fee or oath</td><td></td></tr> <tr><td>1052</td><td>50</td><td>2052</td><td>25</td><td>Surcharge - late provisional filing fee or cover sheet</td><td></td></tr> <tr><td>1053</td><td>130</td><td>1053</td><td>130</td><td>Non-English specification</td><td></td></tr> <tr><td>1812</td><td>2,520</td><td>1812</td><td>2,520</td><td>For filing a request for ex parte reexamination</td><td></td></tr> <tr><td>1804</td><td>920*</td><td>1804</td><td>920*</td><td>Requesting publication of SIR prior to Examiner action</td><td></td></tr> <tr><td>1805</td><td>1,840*</td><td>1805</td><td>1,840*</td><td>Requesting publication of SIR after Examiner action</td><td></td></tr> <tr><td>1251</td><td>110</td><td>2251</td><td>55</td><td>Extension for reply within first month</td><td></td></tr> <tr><td>1252</td><td>400</td><td>2252</td><td>200</td><td>Extension for reply within second month</td><td></td></tr> <tr><td>1253</td><td>920</td><td>2253</td><td>460</td><td>Extension for reply within third month</td><td></td></tr> <tr><td>1254</td><td>1,440</td><td>2254</td><td>720</td><td>Extension for reply within fourth month</td><td></td></tr> <tr><td>1255</td><td>1,960</td><td>2255</td><td>980</td><td>Extension for reply within fifth month</td><td></td></tr> <tr><td>1401</td><td>320</td><td>2401</td><td>160</td><td>Notice of Appeal</td><td></td></tr> <tr><td>1402</td><td>320</td><td>2402</td><td>160</td><td>Filing a brief in support of an appeal</td><td></td></tr> <tr><td>1403</td><td>280</td><td>2403</td><td>140</td><td>Request for oral hearing</td><td></td></tr> <tr><td>1451</td><td>1,510</td><td>1451</td><td>1,510</td><td>Petition to institute a public use proceeding</td><td></td></tr> <tr><td>1452</td><td>110</td><td>2452</td><td>55</td><td>Petition to revive - unavoidable</td><td></td></tr> <tr><td>1453</td><td>1,280</td><td>2453</td><td>640</td><td>Petition to revive - unintentional</td><td></td></tr> <tr><td>1501</td><td>1,280</td><td>2501</td><td>640</td><td>Utility issue fee (or reissue)</td><td></td></tr> <tr><td>1502</td><td>460</td><td>2502</td><td>230</td><td>Design issue fee</td><td></td></tr> <tr><td>1503</td><td>620</td><td>2503</td><td>310</td><td>Plant issue fee</td><td></td></tr> <tr><td>1460</td><td>130</td><td>1460</td><td>130</td><td>Petitions to the Commissioner</td><td></td></tr> <tr><td>1807</td><td>50</td><td>1807</td><td>50</td><td>Processing fee under 37 CFR 1.17(q)</td><td></td></tr> <tr><td>1808</td><td>180</td><td>1808</td><td>180</td><td>Submission of Information Disclosure Stmt</td><td></td></tr> <tr><td>8021</td><td>40</td><td>8021</td><td>40</td><td>Recording each patent assignment per property (times number of properties)</td><td></td></tr> <tr><td>1809</td><td>740</td><td>2809</td><td>370</td><td>Filing a submission after final rejection (37 CFR 1.129(a))</td><td></td></tr> <tr><td>1810</td><td>740</td><td>2810</td><td>370</td><td>For each additional invention to be examined (37CFR 1.129(b))</td><td></td></tr> <tr><td>1801</td><td>740</td><td>2801</td><td>370</td><td>Request for Continued Examination (RCE)</td><td></td></tr> <tr><td>1802</td><td>900</td><td>1802</td><td>900</td><td>Request for expedited examination of a design application</td><td></td></tr> </tbody> </table>			Large Entity	Small Entity	Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	1051	130	2051	65	Surcharge - late filing fee or oath		1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet		1053	130	1053	130	Non-English specification		1812	2,520	1812	2,520	For filing a request for ex parte reexamination		1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action		1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action		1251	110	2251	55	Extension for reply within first month		1252	400	2252	200	Extension for reply within second month		1253	920	2253	460	Extension for reply within third month		1254	1,440	2254	720	Extension for reply within fourth month		1255	1,960	2255	980	Extension for reply within fifth month		1401	320	2401	160	Notice of Appeal		1402	320	2402	160	Filing a brief in support of an appeal		1403	280	2403	140	Request for oral hearing		1451	1,510	1451	1,510	Petition to institute a public use proceeding		1452	110	2452	55	Petition to revive - unavoidable		1453	1,280	2453	640	Petition to revive - unintentional		1501	1,280	2501	640	Utility issue fee (or reissue)		1502	460	2502	230	Design issue fee		1503	620	2503	310	Plant issue fee		1460	130	1460	130	Petitions to the Commissioner		1807	50	1807	50	Processing fee under 37 CFR 1.17(q)		1808	180	1808	180	Submission of Information Disclosure Stmt		8021	40	8021	40	Recording each patent assignment per property (times number of properties)		1809	740	2809	370	Filing a submission after final rejection (37 CFR 1.129(a))		1810	740	2810	370	For each additional invention to be examined (37CFR 1.129(b))		1801	740	2801	370	Request for Continued Examination (RCE)		1802	900	1802	900	Request for expedited examination of a design application	
Large Entity	Small Entity	Fee Description	Fee Paid																																																																																																																																																																																
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																																																																																																																																																
1051	130	2051	65	Surcharge - late filing fee or oath																																																																																																																																																																															
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet																																																																																																																																																																															
1053	130	1053	130	Non-English specification																																																																																																																																																																															
1812	2,520	1812	2,520	For filing a request for ex parte reexamination																																																																																																																																																																															
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																															
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action																																																																																																																																																																															
1251	110	2251	55	Extension for reply within first month																																																																																																																																																																															
1252	400	2252	200	Extension for reply within second month																																																																																																																																																																															
1253	920	2253	460	Extension for reply within third month																																																																																																																																																																															
1254	1,440	2254	720	Extension for reply within fourth month																																																																																																																																																																															
1255	1,960	2255	980	Extension for reply within fifth month																																																																																																																																																																															
1401	320	2401	160	Notice of Appeal																																																																																																																																																																															
1402	320	2402	160	Filing a brief in support of an appeal																																																																																																																																																																															
1403	280	2403	140	Request for oral hearing																																																																																																																																																																															
1451	1,510	1451	1,510	Petition to institute a public use proceeding																																																																																																																																																																															
1452	110	2452	55	Petition to revive - unavoidable																																																																																																																																																																															
1453	1,280	2453	640	Petition to revive - unintentional																																																																																																																																																																															
1501	1,280	2501	640	Utility issue fee (or reissue)																																																																																																																																																																															
1502	460	2502	230	Design issue fee																																																																																																																																																																															
1503	620	2503	310	Plant issue fee																																																																																																																																																																															
1460	130	1460	130	Petitions to the Commissioner																																																																																																																																																																															
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)																																																																																																																																																																															
1808	180	1808	180	Submission of Information Disclosure Stmt																																																																																																																																																																															
8021	40	8021	40	Recording each patent assignment per property (times number of properties)																																																																																																																																																																															
1809	740	2809	370	Filing a submission after final rejection (37 CFR 1.129(a))																																																																																																																																																																															
1810	740	2810	370	For each additional invention to be examined (37CFR 1.129(b))																																																																																																																																																																															
1801	740	2801	370	Request for Continued Examination (RCE)																																																																																																																																																																															
1802	900	1802	900	Request for expedited examination of a design application																																																																																																																																																																															
1. BASIC FILING FEE <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Large Entity</th> <th style="text-align: left;">Small Entity</th> <th style="text-align: left;">Fee Description</th> <th style="text-align: left;">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr><td>1001</td><td>740</td><td>2001</td><td>370</td><td>Utility filing fee</td><td></td></tr> <tr><td>1002</td><td>330</td><td>2002</td><td>165</td><td>Design filing fee</td><td></td></tr> <tr><td>1003</td><td>510</td><td>2003</td><td>255</td><td>Plant filing fee</td><td></td></tr> <tr><td>1004</td><td>740</td><td>2004</td><td>370</td><td>Reissue filing fee</td><td></td></tr> <tr><td>1005</td><td>160</td><td>2005</td><td>80</td><td>Provisional filing fee</td><td>80.00</td></tr> <tr><td colspan="5" style="text-align: right;">SUBTOTAL (1) (\$) 80.00</td></tr> </tbody> </table>		Large Entity	Small Entity	Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	1001	740	2001	370	Utility filing fee		1002	330	2002	165	Design filing fee		1003	510	2003	255	Plant filing fee		1004	740	2004	370	Reissue filing fee		1005	160	2005	80	Provisional filing fee	80.00	SUBTOTAL (1) (\$) 80.00					2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Large Entity</th> <th style="text-align: left;">Small Entity</th> <th style="text-align: left;">Fee Description</th> <th style="text-align: left;">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr><td>1202</td><td>18</td><td>2202</td><td>9</td><td>Claims in excess of 20</td><td></td></tr> <tr><td>1201</td><td>84</td><td>2201</td><td>42</td><td>Independent claims in excess of 3</td><td></td></tr> <tr><td>1203</td><td>280</td><td>2203</td><td>140</td><td>Multiple dependent claims, if not paid</td><td></td></tr> <tr><td>1204</td><td>84</td><td>2204</td><td>42</td><td>** Reissue independent claims over original patent</td><td></td></tr> <tr><td>1205</td><td>18</td><td>2205</td><td>9</td><td>** Reissue claims in excess of 20 and over original patent</td><td></td></tr> <tr><td colspan="5" style="text-align: right;">SUBTOTAL (2) (\$) 0.00</td></tr> </tbody> </table>		Large Entity	Small Entity	Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	1202	18	2202	9	Claims in excess of 20		1201	84	2201	42	Independent claims in excess of 3		1203	280	2203	140	Multiple dependent claims, if not paid		1204	84	2204	42	** Reissue independent claims over original patent		1205	18	2205	9	** Reissue claims in excess of 20 and over original patent		SUBTOTAL (2) (\$) 0.00																																																																																														
Large Entity	Small Entity	Fee Description	Fee Paid																																																																																																																																																																																
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																																																																																																																																																
1001	740	2001	370	Utility filing fee																																																																																																																																																																															
1002	330	2002	165	Design filing fee																																																																																																																																																																															
1003	510	2003	255	Plant filing fee																																																																																																																																																																															
1004	740	2004	370	Reissue filing fee																																																																																																																																																																															
1005	160	2005	80	Provisional filing fee	80.00																																																																																																																																																																														
SUBTOTAL (1) (\$) 80.00																																																																																																																																																																																			
Large Entity	Small Entity	Fee Description	Fee Paid																																																																																																																																																																																
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																																																																																																																																																
1202	18	2202	9	Claims in excess of 20																																																																																																																																																																															
1201	84	2201	42	Independent claims in excess of 3																																																																																																																																																																															
1203	280	2203	140	Multiple dependent claims, if not paid																																																																																																																																																																															
1204	84	2204	42	** Reissue independent claims over original patent																																																																																																																																																																															
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent																																																																																																																																																																															
SUBTOTAL (2) (\$) 0.00																																																																																																																																																																																			
Other fee (specify) _____ SUBTOTAL (3) (\$) 0.00																																																																																																																																																																																			
*Reduced by Basic Filing Fee Paid																																																																																																																																																																																			

SUBMITTED BY		Complete (if applicable)	
Name (Print/Type)	Thomas J. Englemmer	Registration No. (Attorney/Agent)	28,711
Signature		Telephone	617-439-2948
		Date	November 27, 2002

Supplemental Application Data Sheet**Application Information**

Application number::	Not Yet Assigned
Filing Date::	11/27/02
Subject Matter::	Utility
Suggested Group Art Unit::	N/A
CD-ROM or CD-R?::	None
Sequence submission?::	None
Computer Readable Form (CRF)?::	No
Title::	ANTIOXIDANT-FUNCTIONALIZED POLYMERS
Attorney Docket Number::	005363-3126
Request for Early Publication?::	No
Request for Non-Publication?::	No
Small Entity?::	Yes
Petition included?::	No
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	India
Status::	Full Capacity
Given Name::	Amarjit
Family Name::	Singh
City of Residence::	Medford
State or Province of Residence::	MA
Street of mailing address::	8 Brooks Park, Apt. 25
City of mailing address::	Medford
State or Province of mailing address::	MA
Postal or Zip Code of mailing address::	02155

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: David
Middle Name:: L.
Family Name:: Kaplan
City of Residence:: Concord
State or Province of Residence:: MA
Street of mailing address:: 46 Pond Street
City of mailing address:: Concord
State or Province of mailing address:: MA
Postal or Zip Code of mailing address:: 01742

Correspondence Information

Correspondence Customer Number:: 021125

Representative Information

Representative Customer Number:: 021125

ANTIOXIDANT-FUNCTIONALIZED POLYMERS

Field of the Invention

The technical field of this invention is polymer chemistry and in particular the production
5 and uses of antioxidant-functionalized polymers.

Background of the Invention

Nearly all foods, beverages, and pharmaceutical agents undergo gradual changes during
storage. Ignoring degradation caused by microorganisms, spoiling is typically caused by the
10 presence of oxygen and the products of chemical oxidation. The process of auto-oxidation,
which leads to the development of rancidity, flavor and color changes, involves a free radical
chain mechanism. In addition, lipids deteriorate due to oxidation, especially at elevated
temperatures. Susceptibility to oxidation depends upon the degree of unsaturation. Since almost
every product including foodstuff, pharmaceuticals, photochemicals, adhesives, and polymer
15 precursors undergo oxygen degradation, there is a well recognized need for methods and
compositions that can counteract the damaging effects of oxygen.

Preservatives with antioxidant activity are commonly added to packaged foods to
scavenge the oxygen radicals. However, many preservatives used for food, medicine and other
personal care products have been associated with adverse side effects. Therefore, a major
20 concern in the area of human health and well being is the excessive use and exposure to these
commonly used synthetic compounds, which may lead to unwanted and detrimental effects.
Examples of such adverse effects include allergies to benzoic acid and sulphites, the production
of carcinogenic nitrosamines from nitrites, and the carcinogenic effects of butylated
hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). Typically these preservatives are
25 used in ways that allow them to be consumed or absorbed through the skin, leading to
accumulating amounts of these compounds in human beings. Consequently, a need exists for an
oxygen scavenging system that both utilizes natural or organic compounds and/or reduces the
absorption of such compounds into the body.

Currently used strategies for protecting foodstuff and the like include coating oxygen sensitive materials with antioxidant compositions, coating the antioxidants themselves with substances that allow for sustained release, and mixing antioxidants with carriers such as polymers. However, existing methods and compositions typically allow the oxygen scavenging material to leach out of its carrier into the oxygen sensitive materials.

Furthermore, many antioxidants are also inherently susceptible to oxygen degradation, which renders them not functional or less potent in their ability to scavenge free radicals over time. Thus, the industry would greatly benefit from a system in which the antioxidant could be immobilized but yet fully functional. Such an improvement could positively affect manufacturing procedures, quality of goods, efficacy of pharmaceuticals, as well as, the safety of certain medical materials and procedures.

Accordingly, there exists a need for new methods and compositions that provide improved oxygen scavenging capabilities.

Summary of the Invention

Methods and compositions are disclosed for the preparation of free radical scavenging polymers and polymer films functionalized with antioxidants. Enzymatic and chemical tailoring of monomers to include antioxidants followed by enzymatic polymerization is described. These antioxidant functionalized polymers can increase shelf life and quality of food products, as well as, increase effectiveness of pharmaceutical agents when used as packaging or as coatings on packaging for oxygen sensitive materials. The novel enzymatic covalent coupling of antioxidants to a polymer enhances the free radical scavenging ability of packaging while also inhibiting the escape of the antioxidants, and thus limiting exposure and/or absorption by an individual. In addition to its use in food or pharmaceutical packaging, methods are disclosed for using the antioxidant coupled polymers in a variety of applications including as coatings on the inside of medical devices, such as stents and catheters, which would substantially reduce free radical damage and/or oxygen depletion during medical procedures. Furthermore, through the enzymatic coupling of antioxidants to biodegradable polymers, controlled delivery and sustained release of an antioxidant to a subject is possible.

The present invention is based, in part, on the discovery of a method of coupling of antioxidants to monomers followed by enzymatic polymerization which retains antioxidant function. The functionalized polymer can be readily processed into films, fibers or other shaped forms depending on intended use, behaving like the unmodified polymer in many respects with added antioxidant functionality. The present invention also discloses a method of enzymatically coupling antioxidants to polymers that is a significant improvement over known chemical methods. The reactions are easily scalable so that large quantities can be generated; therefore, the methods are easily adapted to high through-put selective coupling while still allowing control over the degree of substitution. Furthermore, enzymes can be engineered to allow specific coupling tailored to the desired antioxidant and/or monomer.


In one embodiment, the invention makes use of organic coupling procedures and biochemistry methods of enzymology to enzymatically couple antioxidants to polymers and polymerize antioxidant functionalized monomers. Non-limiting examples of antioxidants that can be coupled using the present methods include, but are not limited to, ascorbic acid, vitamin E derivatives, tocol, α -tocopherol, β -tocopherol, γ -tocopherol, ϕ -tocopherol, ϵ -tocopherol, ξ 1-tocopherol, ξ 2-tocopherol, η -tocopherol, vitamin B derivatives, thiamine, cyanocobalamin, ergocalciferol, cholecalciferol, vitamin K derivatives, phytonadione, menaquinone, quercetin, vitamin A derivatives, retinol, retinal, 3,4-didehydroretinol, α -carotene, β -carotene, δ -carotene, γ -carotene, cryptoxanthin, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, alpha-lipoic acid, glutathione, carotenoids, allylic sulfides, selegiline, N-actylcysteine, lecithin, tartaric acid, caffeic acid, diaryl amines, thioethers, quinones, tannins, xanthenes, procyanidins, porphrins, phenolphthalein, indophenol, coumarins, flavones, flavanones, and isomers derivatives, and combinations thereof. In one embodiment, the resultant functionalized polymer has at least 70% of the monomeric units coupled to antioxidants. Preferably, 90% of the monomeric units are functionalized. More preferably, at least one antioxidant is coupled to each monomer.

A major concern in many areas of human health and well being is the excessive use and exposure to chemical antioxidants. Thus, there is renewed interest in the potential of "natural"

and more water soluble antioxidants. In one embodiment, the antioxidants coupled to the monomers are organic compounds, which are not only not harmful, but have beneficial health effects. In addition, the covalent coupling of the antioxidants to non-biodegradable monomers prevents absorption of the monomers by an individual while protecting oxygen sensitive materials from degradation.

In one aspect of the present invention, a method for the enzymatic synthesis of functionized polymers is disclosed. Following the activation of monomer units, antioxidants can be coupled to the monomers. In one embodiment, the monomers are functionalized with antioxidants using chemical synthesis. In a preferred embodiment, the monomers are enzymatically functionalized with antioxidants through the selective, enzymatic covalent coupling of the antioxidant. The monomers can be enzymatically polymerized following antioxidant tailoring. The choice of monomer and enzyme is relevant to the use and application of the resultant antioxidant functionalized polymer. Non-limiting examples of monomers include, but are not limited to, vinylbenzoic acid, amino acids, amino acid derivatives, carbohydrates, lactones, esters, olefins, amides, urethanes, acrylides, vinyl monomers, vinyl ethers, acetals, aryl sulfones, ether sulfones, imides, etherketones, phenylene oxides, phenylene sulfides, carbonates, epoxides, phenolics, aminoplasts, saphorolactones, nucleosides, and dendrimers. In one embodiment, a lipase is used to catalyze transesterification resulting in covalent attachment of the antioxidant to the monomer through selective acylation of the primary hydroxyl group of the antioxidant. In another embodiment, horseradish peroxidase (HRP) is used to catalyze the polymerization of functionalized monomers.

In one embodiment, vinyl polymers are formed with pendent antioxidant functional groups. In a preferred embodiment, vinyl monomers can be selectively enzymatically coupled to the primary hydroxyl group of ascorbic acid. The ascorbyl coupled polymer with inherent antioxidant activity can have the core structure shown below:



wherein Y is absent, C_2H_2O , C_7H_4O or a linking group; Z is selected from the group consisting of O, S, N, C, CH, C_6H_3 , C_6H_4 , C_aH_b , $C_6H_{10}O_2$, and $C_aH_bO_m$, wherein a, b, and m are integers; R is selected from the group consisting of absent, hydrogen, oxygen, an alkyl, a hydroxy, an aryl, an aliphatic group, an aromatic group, an acyl group, an alkoxy group, an alkylene group, an alkenylene group, an alkynylene group, a hydroxycarbonylalkyl group, an anhydride, a halide, an amide, an amine, and a heterocyclic aromatic group; and n is an integer greater than or equal to one denoting the degree of polymerization.

10 In this embodiment, the enzymatic coupling methods of the present invention are based on the use of mild and highly selective enzymes to covalently attach an antioxidant compound, which retains its activity, to a vinyl polymer. The enzymatic strategy is a significant improvement over chemical approaches. Chemical coupling of the antioxidant to the polymer is extremely difficult, results in the mixture of products, requires many more steps leading to much lower yields than the enzymatic method described in the present invention. Enzymatic coupling allows selective coupling to the hydroxyl group of interest without the need for protecting groups.

20 In one embodiment, the enzyme *Candida antarctica* lipase can be used to specifically couple the primary hydroxyl group of ascorbic acid to an activated monomer. This hydroxyl group has been implicated in the initial steps of ascorbic acid degradation. Therefore, stabilizing this reactive hydroxyl group can reduce the susceptibility of ascorbic acid to oxygen degradation leading to added stability and improved effectiveness.

25 In one aspect, the present invention can be used to protect oxygen sensitive material from degradation. Coupling of the antioxidant to a polymer, and thus preventing absorption and/or exposure of these compounds by a person is an improvement over antioxidant mixtures

or emulsions which are added directly to food or pharmaceutical agent. In one embodiment, the present invention can be used as a packaging for foods and beverages such that any oxygen leading to free radicals will be scavenged right at the packaging surface, thus avoiding the need to add bulk antioxidants into the product. The antioxidant-coupled polymer can be cast into a film, fiber, coating, sheet, and combinations thereof. In another embodiment, a second oxygen impermeable packaging material can be applied over the antioxidant-coupled polymer adding further protection to the sensitive material. The present invention can be used to protect food or pharmaceutical agents while not changing the flavor, odor, color, efficacy, or organoleptic properties.

In another embodiment, the present invention can be used as a medical device in which at least one surface which is in direct contact with oxygen sensitive material is coated with antioxidant functionalized polymers so as to protect oxygen sensitive material from degradation. The medical device can be an implantable medical device selected from the group consisting of dialysis apparatus, stents, filtration apparatus, catheters, sutures, tubings, syringes, endoscopes, and prostheses. In another embodiment, the medical device is coated with antioxidant coupled biodegradable polymers such that the antioxidant is slowly released upon degradation and can be absorbed by the subject.

In another aspect, the present invention describes a method of controlled delivery of an antioxidant to a subject involving coupling of antioxidants to each of a plurality of biodegradable monomers which are then enzymatically polymerized. In one embodiment, the antioxidants are enzymatically coupled to a plurality of biodegradable monomers. The resultant antioxidant coupled polymer will degrade over time and deliver the antioxidant at a controlled rate.

Antioxidants are important in reducing the impact of aging-related phenomena in humans, thus high contents of vitamin C and other natural antioxidants are used by many consumers. The antioxidant coupled biodegradable polymers may be designed so that release of the antioxidant from the polymer is controlled and scalable based upon need. In one embodiment, the functionalized biodegradable polymer is implantable. In another embodiment, it is ingestible.

In yet another embodiment, it can be applied topically, as an ointment, cosmetic, or other personal care product. This embodiment may be particularly useful to prevent aging effects on

the skin. The biodegradable monomers can be selected from, but not limited to, the group consisting of polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids, "pseudo" amino acids, esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, biodegradable dendrimers, and combinations thereof. The method comprises coupling at least 1% of the activated monomers with antioxidants, preferably at least 10%, more preferably at least 50%. More preferable at least one antioxidant is coupled per monomer. In another embodiment, a controlled delivery system for antioxidants comprises an antioxidant bound to a biodegradable polymer, wherein the antioxidant is present in an amount from about 20% to about 80% (w/w).

10

The present invention has many benefits over known methods of antioxidant scavenging techniques. Antioxidants specifically coupled to monomer units ensure broad and effective dispersion of the antioxidant while eliminating the particle dispersion problem of emulsions or mixtures. Since the antioxidants do not leach out of the polymer matrix, the compositions are non-staining, non-discoloring, non-toxic, odorless and tasteless. Immobilizing the antioxidant also improves its long term stability. In addition, the present invention is compatible with use of other antioxidants, preservatives and stabilizers and may provide a simple solution to recycling of certain compounds. For example, the maintenance of vitamin E in its non-radical reduced form is dependent upon the vitamin C. Therefore, if vitamin C or vitamin E is coupled to the polymer and the other is added to oxygen sensitive material, the potency and effectiveness of antioxidant protection would be greatly improved. This novel method of enzymatically polymerizing antioxidant-coupled monomers to functionalized polymers is highly specific and adaptable to high-through put manufacturing. In addition, enzymatically coupling the antioxidants to biodegradable polymers, allows a variety of medicinal uses including a controlled delivery system for antioxidants used in treatment and/or prevention of diseases.

15

20

25

Brief Description of the Drawings

Figure 1 is a schematic of the enzymatic coupling of ascorbic acid to p-vinylbenzoic acid and enzymatic polymerization to form a polymerized L-ascorbyl 4-vinylbenzoate (4);

5

Figure 2 is a ^1H NMR spectrum of polymerized L-ascorbyl 4-vinylbenzoate (4);

Figure 3 is a MALDI-TOF spectrum of polymerized L-ascorbyl 4-vinylbenzoate (4);

10

Figure 4 is a schematic of the enzymatic coupling of ascorbic acid to p-hydroxyphenyl acetic acid followed by enzymatic polymerization to form polymerized L-ascorbyl 4-hydroxyphenyl acetate (8);

15

Figure 5 is a schematic of the coupling of retinol to p-vinylbenzoic acid followed by enzymatic polymerization to form polymerized retinyl 4-vinylbenzoate (11);

Figure 6 is a schematic of the coupling of retinol to p-hydroxyphenyl acetic acid followed by enzymatic polymerization to form polymerized retinyl 4-hydroxybenzylacetate (15); and

20

Figure 7 is a schematic of the coupling of tocol to p-vinylbenzoic acid followed by enzymatic polymerization to form polymerized 2-methyl-2-(4, 8, 12-trimethyltridecyl)-6-(4-vinylbenzoyl)-chromanol (20);

25

Figure 8 is a schematic of the lipase catalyzed ring opening polymerization of caprolactone using the primary hydroxyl group of ascorbic acid as the initiator.

Detailed Description of the Invention

The present invention provides methods and compositions for coupling antioxidants to monomers and polymerizing the functionalized monomers. Methods of selective enzymatic covalent coupling are disclosed. The invention provides a method for packaging foodstuff and pharmaceuticals that protects from oxidative degradation. The methods and compositions of the invention can be used to prevent or slow degradation of oxygen sensitive materials. Use of the invention to coat biomedical devices that transport oxygen sensitive materials is also disclosed. In addition, a method for administering a sustained and controlled amount of the antioxidant to a subject following the predicted degradation of a biodegradable polymer is described. The practice of the present invention employs, unless otherwise indicated, conventional methods of organic chemistry, biochemistry, and polymer chemistry.

So that the invention is more clearly understood, the following terms are defined:

The term "antioxidant" as used herein refers to a substance that, when present in a mixture or structure containing an oxidizable substrate molecule (e.g., an oxidizable biological molecule or oxidizable indicator), significantly delays or prevents oxidation of the oxidizable substrate molecule. Antioxidants can act by scavenging biologically important reactive free radicals or other reactive oxygen species (e.g., O_2^- , H_2O_2 , $HOCl$, ferryl, peroxy, peroxyxynitrite, and alkoxy), or by preventing their formation, or by catalytically converting the free radical or other reactive oxygen species to a less reactive species. Antioxidants can be used to prevent food spoilage and to prevent or slow degradation or reduction in the effectiveness of pharmaceutical agents. Antioxidants can be separated into two classes, lipid antioxidants, and aqueous antioxidants. Examples of lipid antioxidants include, but are not limited to, carotenoids (e.g. lutein, zeaxanthin, β -cryptoxanthin, lycopene, α -carotene, and β -carotene), which are located in the core lipid compartment, and tocopherols (e.g. vitamin E, tocol, α -tocopherol, γ -tocopherol, and δ -tocopherol), which are located in the interface of the lipid compartment, and retinoids (e.g. vitamin A, retinol, and retinyl palmitate) and fat-soluble polyphenols such as quercetin. Examples of aqueous antioxidants include, but are not limited to, ascorbic acid and its oxidized form, "dehydroascorbic acid", uric acid and its oxidized form, "allantoin", bilirubin,

albumin and vitamin C and water-soluble polyphenols such as catechins, which have high affinity to the phospholipid membranes, isoflavones, and procyanidins.

When one more antioxidants are added to a test sample or assay, a detectable decrease in the amount of a free radical, such as superoxide, or a nonradical reactive oxygen species, such as hydrogen peroxide, may be seen in the sample, compared with a sample untreated with the antioxidant (*i.e.* control sample) or assay reaction. Electron spin resonance (ESR) can be used to measure free radicals directly. However, numerous indirect methods exist such as monitoring the change in antioxidant status, assays that trap hydroxyl radicals, and monitoring degradation products caused by free radicals (*i.e.* lipid peroxidation). Suitable concentrations of antioxidants measured to produce the desired change or amelioration, (*e.g.*, an efficacious or therapeutic dose) can be determined by various methods, including generating an empirical dose-response curve.

The term "free radical" as used herein refers to molecules containing at least one unpaired electron. Most molecules contain even numbers of electrons, and their covalent bonds normally consist of shared electron pairs. Cleavage of such bonds produces two separate free radicals, each with an unpaired electron (in addition to any paired electrons). They may be electrically charged or neutral and are highly reactive and usually short-lived. They combine with one another or with atoms that have unpaired electrons. In reactions with intact molecules, they abstract a part to complete their own electronic structure, generating new radicals, which go on to react with other molecules. Such chain reactions are particularly important in decomposition of substances at high temperatures. In the body, oxidized (see oxidation-reduction) free radicals can damage tissues. Antioxidant nutrients (*e.g.*, vitamins C and E, selenium, polyphenols) may reduce these effects. Heat, ultraviolet light, and ionizing radiation all generate free radicals. Free radicals are generated as a secondary effect of oxidative metabolism. An excess of free radicals can overwhelm the natural protective enzymes such as superoxide dismutase, catalase, and peroxidase. Free radicals such as hydrogen peroxide (H_2O_2), hydroxyl radical (HO^\bullet), singlet oxygen (1O_2), superoxide anion radical (O_2^\bullet), nitric oxide radical (NO^\bullet), peroxy radical (ROO^\bullet), peroxynitrite ($ONOO^-$) can be in either the lipid or aqueous compartments.

The term "polymer" as used herein refers to a large molecule built up by the repetition of small, simple chemical units, monomers, formed in an association reaction in which many molecules come together to form one large molecule. The length of the polymer chain is specified by the number of repeat units in the chain. The resulting polymer can have more than
 5 one type of repeating monomer.

The term "copolymer" as used herein refers to a polymer made from two (or more) different monomer building blocks., such as styrene-butadiene rubber (SBR).

10 The term "monomer" as used herein refers to a starting material from which a polymer is formed and encompasses homogenous and heterogeneous combinations thereof. The starting units may be selected from, but not limited to, the group consisting of vinylbenzoic acid, amino acids, amino acid derivatives, carbohydrates, lactones, lactides, cyclic carbonates, esters,
 15 sulfones, imides, etherketones, phenylene oxides, phenylene sulfides, carbonates, epoxides, phenolics, aminoplasts, saphorolactones, nucleosides, and dendrimers and combinations thereof. The term "monomer" is also intended to include biodegradable monomers including, but not limited to, polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids, "pseudo" amino acids,
 20 esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, and biodegradable dendrimers and combinations thereof.

The term "linking group," as used herein, refers to any moiety capable of joining two atoms, *e.g.*, the adjacent carbon and oxygen. The term linking group is intended to include, but
 25 not limited to, carbon (C), oxygen (O), sulfur (S), nitrogen (N), CH, C₆H₃, C₆H₄, C_aH_b, C₆H₁₀O₂, C₂H₂O, C₇H₄O, and C_aH_bO_m, wherein a, b, and m are integers. The linking group can also be selected from the group consisting of an alkyl, a hydroxy, an aryl, an aliphatic group, an aromatic group, an acyl group, an alkoxy group, an alkylene group, an alkenylene group, an alkynylene group, a hydroxycarbonylalkyl group, an anhydride, an amide, an amine, and a heterocyclic
 30 aromatic group, vinylbenzoic acid, amino acids, amino acid derivatives, carbohydrates, lactones, lactides, cyclic carbonates, esters, olefins, amides, urethanes, acrylides, vinyl monomers, vinyl

ethers, acetals, aryl sulfones, ether sulfones, imides, etherketones, phenylene oxides, phenylene sulfides, carbonates, epoxides, phenolics, aminoplasts, saphorolactones, nucleosides, dendrimers, polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, "pseudo" amino acids, esteramides, orthoesters, saphorolactones, nucleosides, biodegradable dendrimers, and segments and combinations thereof. The linking group can be a biodegradable moiety. The linking group can also be absent resulting in the direct bonding of the carbon and oxygen.

The term "oxygen impermeable" as used herein refers to the inability of at least 50% of oxygen molecules to freely pass through such material.

The term "subject" as used herein refers to any living organism in which an immune response is elicited. The term "subject" includes, but is not limited to, humans, nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.

The phrase "free radical associated disorder" as used herein refers to a pathological condition of in a subject that results at least in part from the production of or exposure to free radicals, for example, oxyradicals, or other reactive oxygen species *in vivo*. The term "free radical associated disorder" encompasses pathological states that are recognized in the art as being conditions wherein damage from free radicals is believed to contribute to the pathology of the disease state, or wherein administration of a free radical inhibitor (e.g., desferrioxamine), scavenger (e.g., tocopherol, glutathione), or catalyst (e.g., SOD, catalase) is shown to produce a detectable benefit by decreasing symptoms, increasing survival, or providing other detectable clinical benefits in protecting or preventing the pathological state. Examples of free radical disorders include, but are not limited to, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematosus, myocardial infarction, stroke, traumatic hemorrhage, spinal cord trauma, Crohn's disease, autoimmune diseases (e.g., rheumatoid arthritis, diabetes), cataract

formation, age-related macular degeneration, Alzheimer's disease, uveitis, emphysema, gastric ulcers, oxygen toxicity, neoplasia, undesired cell apoptosis, and radiation sickness. Such diseases can include "apoptosis-related ROS" which refers to reactive oxygen species (e.g., O_2) which damage critical cellular components (e.g., lipid peroxidation) in cells stimulated to undergo apoptosis, such apoptosis-related ROS may be formed in a cell in response to an apoptotic stimulus and/or produced by non-respiratory electron transport chains (i.e., other than ROS produced by oxidative phosphorylation).

The term "oxidative stress" as used herein refers to the level of damage produced by oxygen free radicals in a subject. The level of damage depends on how fast reactive oxygen species are created and then inactivated by antioxidants.

The term "nutraceutical" as used herein refers to an isolated or purified compound or composition generally sold in medicinal forms that have a demonstrated physiological benefit or provide protection against chronic disease. Non-limiting examples of nutraceuticals include soy protein, calcium, vitamin E, isoflavones, and beta-carotene. Functionalized biodegradable polymers would have nutraceutical application, since the dosage can be controlled and sustained over time.

The invention is described in more detail in the following subsections:

I. Antioxidants

A. General

Free radicals are very unstable and react quickly with other compounds beginning a multi-step chain reaction. Free radicals arise normally during metabolism or may result from environmental factors such as pollution, radiation, cigarette smoke, and herbicides. Antioxidants act as scavengers, helping to prevent cell and tissue damage that could lead to cellular damage and disease. While some antioxidants are produced in the body, others come from food. For example, after vitamin E neutralizes a harmful radical it can be recycled back to its original form by interacting with vitamin C. Vitamin C is recycled by interacting with another antioxidant such as glutathione. Antioxidants useful for the present invention may be selected from, but not


limited to, the group consisting of ascorbic acids, vitamin E derivatives, tocopherols, α -tocopherols, β -tocopherols, γ -tocopherols, ϕ -tocopherols, ϵ -tocopherols, ξ 1-tocopherols, ξ 2-tocopherols, η -tocopherols, vitamin B derivatives, thiamines, cyanocobalamins, ergocalciferols, cholecalciferols, vitamin K derivatives, phytonadiones, menaquinones, quercetins, vitamin A derivatives, retinols, retinals, 3,4-didehydroretinols, α -carotenes, β -carotenes, δ -carotenes, γ -carotenes, cryptoxanthins, citric acid, butylated hydroxyanisoles, butylated hydroxytoluenes, alpha-lipoic acids, glutathiones, carotenoids, allylic sulfides, selegilines, N-actylcysteines, lecithins, tartaric acids, caffeic acids, diaryl amines, thioethers, quinones, tannins, xanthenes, procyanidins, porphyrins, phenolphthaleins, indophenol, coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof. Examples 2, 5, and 6 demonstrate that the present methods can be used with a variety of antioxidants, such as ascorbic acid, tocopherol, and retinol.

B. Ascorbic acid

Ascorbic acid ($C_6H_8O_6$), otherwise known as vitamin C or the γ -lactone L-3-ketothreohexuronic acid, is essential to the human diet, since primates and guinea pigs are the only animals unable to produce this essential vitamin. Ascorbic acid is a water-soluble, chain-breaking antioxidant which reacts directly with singlet oxygen, hydroxyl, and superoxide radicals. It also may react with tocopheroxy radicals to regenerate vitamin E. It is an important part of the synthesis of collagen and carnitine, and is the human body's primary water-soluble antioxidant. Ascorbic acid has been associated with the treatment of many disorders including the common cold and cancer through stimulation of the immune system and protecting the body against free radicals. Vitamin C is very important in the healing of wounds and broken bones. It also aids in the production of hemoglobin and red blood cells in the bone marrow. Large doses of vitamin C, taken every day has been shown to reduce asthma symptoms, as well as to lower the risk of glaucoma, cataracts, or cardiovascular disease. Ascorbic acid is used by the adrenal gland to make hormones such as adrenaline, and hormones that regulate blood sugar and blood minerals. It can also be found in large quantities in the brain as it plays an important role in nerve transmission by changing amino acids into neurotransmitters. Ascorbic acid accelerates hydroxylation reactions, in part by donating electrons to metal ion cofactors of hydroxylase enzymes. Hydroxylation reactions are important in collagen synthesis, conversion of lysine to

carnitine, conversion of dopamine to norepinephrine, and in tyrosine metabolism. Through its role in collagen synthesis, ascorbic acid strengthens bones, joints, teeth, gums, artery walls, and all connective tissue in the body. It also catalyzes other enzymatic reactions, such as amidation necessary for maximum activity of the hormones oxytocin, vasopressin, cholecystokinin, and alpha-melanotropin (Arrigoni *et al. Biochim. Biophys. Acta.* 1569: 1-9 (2002)). Deficiency of Vitamin C may lead to soft or bleeding gums, swollen or painful joints, slow-healing wounds and fractures, bruising, nosebleeds, tooth decay, loss of appetite, muscular weakness, skin hemorrhages, capillary weakness, anemia, and impaired digestion.

Under physiological conditions, ascorbic acid gets reversibly oxidized to form dehydroascorbic acid which is then followed by the irreversible hydrolysis of the lactone ring to form the inactive diketogulonic acid. In addition, free ascorbic acid undergoes moisture induced degradation which leads to discoloration and inactivation. As many as eight different compounds were found to be present in the degraded product (Shephard, A. B. *et al. Talanta* 48:585-593 (1999); Shephard A. B. *et al. Talanta* 48: 595-606 (1999); Shephard, A. B. *et al. Talanta* 48: 607-622 (1999)). The possible chemical pathway which results in major degradation products involves the primary hydroxyl group of ascorbic acid. The present invention blocks this step of ascorbic acid degradation. The protocol described in Example 2 describes how the primary hydroxyl group is regioselectively protected via mild enzyme catalyzed transesterification reaction which stops degradation as the active ascorbic acid is covalently attached to the vinyl monomer (Figure 1). The ascorbyl coupled polymer with inherent antioxidant activity can have the core structure shown below:



wherein Y is absent, C_2H_2O , C_7H_4O or a linking group; Z is selected from the group consisting of O, S, N, C, CH, C_6H_3 , C_6H_4 , C_6H_5 , $C_6H_{10}O_2$, and $C_6H_5O_m$, wherein a, b, and m are integers; R is selected from the group consisting of absent, hydrogen, oxygen, an alkyl, a hydroxy, an aryl, an aliphatic group, an aromatic group, an acyl group, an alkoxy group, an alkylene group, an

alkenylene group, an alkynylene group, a hydroxycarbonylalkyl group, an anhydride, a halide, an amide, an amine, and a heterocyclic aromatic group; and n is an integer greater than or equal to one denoting the degree of polymerization. Examples 3 and 5 describe the polymerization of ascorbyl coupled monomers. The resultant ascorbyl coupled polymer retains antioxidant activity
5 as shown in Example 4. In one aspect, the ascorbyl coupled polymer of the present invention could be used to protect oxygen sensitive material from degradation.

The present invention provides methods and compositions that stabilize and inhibit oxidation of ascorbic acid by hindering one of the initial steps in ascorbic acid degradation. Ascorbic acid is highly sensitive to environmental factors such as light, oxygen, and water which
10 lead to its degradation. L-Ascorbic acid is approved for use as a dietary supplement and chemical preservative by the U.S. Food and Drug Administration and is on the FDA's list of substances generally recognized as safe. L-Ascorbic acid has been used in soft drinks as an antioxidant for flavor ingredients, in meat and meat-containing products, for curing and pickling, in flour to improve baking quality, in beer as a stabilizer, in fats and oils as an antioxidant, and in
15 a wide variety of foods for vitamin C enrichment. It is one of the major antioxidant nutrients and has been shown to prevent the conversion of nitrates, such as from tobacco smoke, smog, bacon, lunch meats, and some vegetables, into cancer-causing substances. In one aspect of the invention, the ascorbic acid coupled polymer can be used to stabilize nitrates. In one embodiment, the functionalized polymer could be incorporated into the packaging of food stuff
20 such as bacon, lunch meats, and vegetables. In another embodiment, the ascorbic acid coupled polymer can be used to coat the inside of a bag, carton, box, container, jar or lid of any foodstuff containing package. In yet another embodiment, the functionalized polymer can be coated with a second oxygen impermeable coating. This would be useful for air-tight packaging or vacuum sealed packaging of any oxygen sensitive material. In another embodiment, the ascorbic coupled
25 polymer can be incorporated into cigarette or cigar filters. In yet another embodiment, the present invention may be used as a medical device in which at least one surface, which is in direct contact with oxygen sensitive material, is coated with ascorbyl coupled polymers so as to protect oxygen sensitive material from degradation. The medical device may be an implantable medical device selected from the group consisting of dialysis apparatus, stents, filtration
30 apparatus, catheters, sutures, tubings, syringes, endoscopes, and prostheses. In another

embodiment, the medical device is coated with antioxidant coupled biodegradable polymers such that the antioxidant is slowly released upon degradation and can be absorbed by the subject.

L-Ascorbic acid has been used in stain removers, hair waving preparations; plastics manufacture, photography, and water treatment. In another embodiment, the ascorbic coupled polymer could be used in these applications of L-ascorbic acid, since the immobilized ascorbic acid may be more stable and thus be more useful than the free antioxidant. In addition, better control over placement and release would be attainable in a polymer functionalized with ascorbic acid.

In one embodiment, ascorbic acid coupled polymers can be used to provide protection to oxygen sensitive ingestible materials such as foodstuff, pharmaceutical agents, biological fluids or tissues, without increasing levels of vitamin C in the body. The antioxidant is covalently coupled to the polymer preventing leaching out of the polymer and thus it will not be absorbed by the body. While ascorbic acid is usually non-toxic, at high doses (more than 2,000 mg daily) it can cause diarrhea, gas, or stomach upset. In addition, infants born to mothers ingesting 6,000 mg or more of vitamin C may develop rebound scurvy due to sudden drop in daily intake. Furthermore, vitamin C may interact with other drugs. Although vitamin C may protect the stomach and intestines from injury caused by aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), at high doses of vitamin C (equal to or greater than 500 mg per day) the blood levels of aspirin and other acidic medications may increase. Vitamin C may decrease excretion of acetaminophen in the urine, which may increase blood levels of this medication. Vitamin C may also affect the blood levels of many drugs including diuretics, such as furosemide, beta-blockers, such as propranolol, antibiotics, such as tetracycline, as well as estradiol, an ingredient in some birth control medications and hormone replacement therapies. Since many people who are taking such medication need to accurately control the levels of ascorbic acid ingested, the present invention can be an extremely important for the effectiveness of their treatment. Currently, ingestible antioxidants are readily added to many foodstuff to provide oxygen scavenging protection. However, with the use of the present compositions and methods, these patients will no longer be at risk.

The combination of vitamin C with nitroglycerin and nitrate medications (isosorbide dinitrate and isosorbide mononitrate), used to treat heart disease, reduces the occurrence of nitrate tolerance, an effect by which the body becomes accustomed to the medicine and then requires a period without the medication in order for it to achieve the desired medicinal effect.

- 5 Vitamin C reduces nitrate tolerance which may translate into greater effectiveness of the nitrate medication (Daniel, T. A. *et al. Ann. Pharmacother.* 34 (10): 1193-1197 (2000)).

C. Tocol

- 10 Vitamin E, the major lipid soluble chain-breaking *in vivo* antioxidant, has been shown to have a critical role in disease prevention. Vitamin E exerts its role as an antioxidant by quenching free radicals and preventing structural damage to cells, tissues, organelles and lipids that constitute the membrane by-layer. The generic term, vitamin E, comprises all tocol entities exhibiting the biological activity of d- α -tocopherol. Vitamin E has been associated with immunocompetence, inhibition of mutation formation, repair of membranes and cellular structures to include DNA and glycoproteins. Vitamin E has also been shown to reduce, treat, 15 or modulate a variety of disease states or disorders, such as cancer, chronic inflammation, cardiovascular disease, onset of cataracts, the aging process, and diabetic neuropathy (Fairfield KM *et al. JAMA* 287(23):3116-26 (2002); Sytze Van Dam P. *Diabetes Metab Res Rev* 18(3):176-84 (2002); Brigelius-Flohe R *et al. Am J Clin Nutr* 76(4):703-16 (2002)). In addition, vitamin E has been shown to play a role in neurodegenerative disorders, Alzheimer's 20 disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), tardive dyskinesia, Huntington's disease (HD), and multiple sclerosis, that are associated with oxidative stress resulting from lipid peroxidation (Butterfield DA *et al. Nutr Neurosci* 5(4):229-39 (2002)). Vitamin E also has been shown to have effects that are unrelated to antioxidant activity, such as inhibition of cell proliferation, platelet aggregation and monocyte 25 adhesion, which may result from the interaction of vitamin E with cell components (Ricciarelli R *et al. Biol Chem* 383(3-4):457-65 (2002)).

Eight compounds that exhibit α -tocopherol activity have been found in nature: d- α , d- β , d- δ , d- γ -tocopherols and the tocotrienols (d- α , d- β , d- δ , d- γ). These compounds differ in

the number and position of the methyl groups on the chroman ring. The distribution of the tocopherols varies widely. For example, crude corn and wheat oils may contain as much as 200 mg tocopherols per 100 g, while coconut oil contains very little. α -Tocopherol predominates in safflower oil, γ - and δ -tocopherols are more abundant than α - in soybean, γ - is the prevalent form in corn oil. β -Tocopherol is abundant in wheat germ oil, and is generally found only in traces in other vegetable oils. Tocopherols are extracted commercially from vegetable oilseeds, such as soybean (Bonvehí JS et al. *J AOAC Int* 83(3):627-34 (2000)).

Natural vitamin E exists as a single molecular structure (*RRR*- or *d*- α -tocopherol) derived from vegetable oils, primarily soybean, sunflower, and corn oils. Synthetic vitamin E can be produced commercially by coupling trimethylhydroquinone (TMHQ) with isophytol. The resulting mixture yields eight different compounds, one of which is *d*- α -tocopherol. The other seven stereoisomers have different molecular structures and reduced biological activity compared to natural vitamin E. Both the natural and synthetic forms of vitamin E are available commercially, primarily as their acetate esters.

15 D. Retinol

Vitamin A (retinol) is a fat soluble antioxidant. Vitamin A maintains the skin and mucous membranes, promotes growth, strong bones, healthy skin, hair, teeth and gums, builds up resistance to respiratory infections and shortens the duration of diseases. It also counteracts night blindness, reduces many eye disorders and may reduce cancer. In addition, vitamin A is important for reproduction, growth, and immune function. Topical retinol delivery has demonstrated significant anti-inflammatory effects (Wolf JE Jr. *Adv Ther* 19(3):109-18 (2002)). The best natural sources of vitamin A are green leafy vegetable tops, carrots, red peppers, sweet potatoes, yellow fruits, apricots, fish-liver oil and eggs. Pro-vitamin A carotenoids can also be an important source of the nutrient (Ribaya-Mercado JD *Nutr Rev* 60(4):104-10 (2002)). The RDA (Recommend Dietary Allowance) for adults is 1000 micrograms RE (Retinol Equivalents. 1 RE = 1 microgram retinol or 6 micrograms β -carotene). Excessive amounts of vitamin A, e.g., 100,000 IU/day, can produce severe toxicity.

II. Coupling Antioxidants to Polymers

A. Monomers

The choice of monomers is dependent upon the intended use of the resultant antioxidant coupled polymer. Examples 2, 5, and 6 demonstrate that the present methods of enzymatic coupling of an antioxidant can be used with a variety of monomers. Monomers may be selected from, but not limited to, the group consisting of vinylbenzoic acid, amino acids, amino acid derivatives, carbohydrates, lactones, lactides, cyclic carbonates, esters, olefins, amides, urethanes, acrylides, vinyl monomers, vinyl ethers, acetals, aryl sulfones, ether sulfones, imides, etherketones, phenylene oxides, phenylene sulfides, carbonates, epoxides, phenolics, aminoplasts, saphorolactones, nucleosides, and dendrimers. In addition, monomers may be biodegradable (See below).

In one embodiment, the monomer is a vinyl monomer as illustrated in Figures 1, 5, and 7 and described in Examples 2, 3, 6. In another embodiment, the monomer is a phenolic monomer as illustrated in Figures 4 and 6 and described in Examples 5 and 6. In yet another embodiment, the monomer is a lactone as demonstrated in Figure 8. The monomers can also be cyclic, *e.g.*, lactones, lactides, cyclic carbonates. As demonstrated in Figure 8, the primary hydroxyl group of ascorbic acid can be used as an initiator in the lipase catalyzed ring opening polymerization of cyclic monomers *e.g.*, caprolactone.

B. Enzymatic Coupling Antioxidants to Monomers

Enzymatic coupling of the antioxidant of choice to the monomer involves the use of an appropriate enzyme. Non-limiting examples of enzymes include proteases, which could be used to form amide linkages between the monomer and the antioxidant, glycosidases, which could be used to form glycosidic linkages between the monomer and antioxidant, and lipases. Lipases or triglycerol ester hydrolases are enzymes which catalyze the hydrolysis of fatty acid esters. Although they usually are found in aqueous environments in living systems, some lipases are stable in organic solvents. Lipases are commonly used enzymes for the catalysis of chemospecific, regiospecific, and/or stereospecific hydrolysis of carboxylic acids esters. Schemes 1 and 2 show the lipase catalyzed esterification (1) and transesterification (2), two reactions which can be used to couple the hydroxyl group of an antioxidant to a monomer.



Using vinyl acetate as an acylating agent makes the reaction irreversible. Acetaldehyde
 5 can deactivate some lipases; however, immobilizing the lipase stabilizes the enzyme (Reetz, M.
 T. *Cur. Opin. Chem. Biol.* 6: 145-150 (2002)). *Candida antarctica* lipase, for example, is a well
 characterized, efficient enzyme that can be immobilized. Example 2 describes the use of
Candida antarctica lipase to catalyze transesterification resulting in the covalently attachment of
 the antioxidant, ascorbic acid, to a monomer, vinyl benzoate. The enzyme is used to couple an
 10 ascorbic acid moiety to at least 1% of the monomers, preferably at least 10%, more preferably at
 least 50% of the monomers. More preferably, at least one ascorbic acid moiety is attached to
 each monomer. Immobilization of the enzyme is highly adaptable to industrial applications. In
 addition, genetic engineering and directed evolution methods can be used to specifically design
 an enzyme useful for the covalent attachment of the antioxidant of choice (Rotticci, D. *et al.*
 15 *ChemBioChem* 2: 766-770 (2001)).

C. Enzymatic Polymerization

Polymerization of the functionalized monomers can be done via enzymatic methods. The
 use of enzymes in chemical polymer synthesis has many advantages including high efficiency of
 20 the reactions without the need for harsh reaction conditions (i.e. extreme temperatures, pressure
 or pH) and the ability to be enantiospecific, regiospecific, chemospecific, as well as,
 stereospecific. A recent review of enzymatic polymerization (Kobayashi, S. *et al. Chem. Rev.*
 101 (12): 3793-3818 (2001)) highlights the most well characterized and widely used enzymes
 used for polymerization. Nonlimiting examples of these enzymatic classes include
 25 oxidoreductases (i.e., peroxidase, laccase, and bilirubin oxidase), which can be used for the
 polymerization of polyphenols, polyanilines, and vinyl polymers; transferases (i.e.,
 phosphorylases, synthases, acyl transferases, and glycosyltransferases), which can be used for
 the polymerization of polysaccharides, cyclic oligosaccharides, and polyesters; hydrolases (i.e.,
 glycosidases and lipases), which can be used for the polymerization of polysaccharides,
 30 polyesters, polycarbonates, and poly (amino acid)s; lyases; isomerases; and ligases. In addition,
 advances in genetic engineering allow the production of enzymes specifically designed for a

reaction of interest. For example, enzymes can be engineered to have high efficiency, tight selectivity, or high stability in organic solvents. These enzymatic polymerization techniques and methods are within the scope of the present invention.

5 In a preferred embodiment, horseradish peroxidase (HRP) is used. Horseradish peroxidase is an oxidoreductase isolated from plants that catalyses the oxidation of many phenolic and aromatic amines, mediated by hydrogen peroxide (Akkara, et al. *J. Polym. Sci. Part A: Polymer Chemistry* 29, 1561-1574 (1991); (Rao, et al. *Biotechnology and Bioengineering* 41, 531-540 (1993); Ayyagari et al. *Macromolecules* 28, 5192-5197. (1995);
10 Kobayashi et al. *Chem. Rev.* 101, 3793-3818 (2001)). Generally, molar equivalents of monomer to hydrogen peroxide are used, although recent studies with vinyl monomers have shown that amount of the hydrogen peroxide can be reduced 40-50 fold compared to monomer with the addition of a β -diketone to facilitate the free-radical process (Singh et al. *Biomacromolecules* 1, 592-596 (2000); (Singh et al. *J. Macromol. Sci.- Pur and Applied Chemistry* A38, 1219-1230
15 (2001); (Kalra et al. *Biomacromolecules* 1, 501-505 (2000); (Teixeira et al. *Macromolecules* 32, 70-72 (1999); (Durand et al. *Polymer* 42, 5515-5521 (2001)). Horseradish peroxidase catalyzed polymerization of L-ascorbyl 4-vinylbenzoate (3) with oxidant hydrogen peroxide and initiator 2,4-pentanedione is shown in Example 3.

20 **III. Coupling Antioxidants to Biodegradable Polymers**

A. Biodegradable Polymers

Biodegradable polymers have proven to be greatly important in medical applications over the last three decades. Polymers composed of lactic acid, glycolic acid, poly(dioxanone), poly(trimethylene carbonate) copolymers, and poly(caprolactone) homopolymers and
25 copolymers are widely accepted for use as medical devices. Research continues on polyanhydrides, polyorthoesters, polyphosphazenes, and other biodegradable polymers. In one embodiment of the present invention, antioxidants can be enzymatically coupled to biodegradable monomers, such that the resulting biodegradable polymer retains antioxidant function. Non-limiting examples of biodegradable monomer comprise of polyesters, glycolides,
30 lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates,

carbonates, amino acids, "pseudo" amino acids, esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, and biodegradable dendrimers and combinations thereof.

Antioxidant-coupled biodegradable polymers have a wide variety of uses as medical devices, controlled drug delivery, as well as packaging materials. In one embodiment, the antioxidant-coupled biodegradable polymer can be implanted into a subject, such that antioxidants are released upon degradation. The implanted antioxidant polymer may be used to help stabilize healing bones. The biodegradable polymer can be engineered such that the rate of degradation is slow enough so that the healing bone can accommodate the increasing load. The released antioxidants could help improve healing and regrowth.

Biodegradable polymers are tremendously useful as the basis for drug delivery, either as a drug delivery system alone or in conjunction to functioning as a medical device. In one aspect of the invention, a method of controlled delivery of an antioxidant to a subject is described in which antioxidants are coupled to biodegradable monomers, which can then be polymerized (see Example 3 and section on Enzymatic Polymerization). The resultant antioxidant coupled polymer degrades at a rate consistent with an effective administration rate of the antioxidant. The antioxidant bound to a biodegradable polymer in the controlled delivery system is present in an amount from about 20% to about 80% (w/w). Antioxidants are chosen based upon the application, and the biodegradable monomers may be either synthetic or natural. Natural antioxidants, such as ascorbic acid and tocopherols, not only preserve food and improve flavor, but also protect against pathological effects of free radicals which are associated with altered states such as cancer, cardiovascular disease and aging. The antioxidant coupled polymer may be cast into a shaped form from the group consisting of, but not limited to, a film, a fiber, a coating, a sheet, or combinations thereof. In one embodiment, the controlled delivery system may be implanted into a subject. In another embodiment, the controlled delivery system may be ingested. In a third embodiment, the controlled delivery system may be used as a topical ointment.

In one embodiment, the controlled delivery system consists of an antioxidant coupled homopolymer matrix. In another embodiment, the antioxidant coupled polymer matrix is a

copolymer. At least 1% of the monomeric units are functionalized with antioxidants, preferably 10%, more preferably at least 50%, and most preferably at least one antioxidant is coupled to each monomer. More than one antioxidant can be used in the controlled delivery system. For example, vitamin E (α -tocopherol) and vitamin C, which recycle each other, can both be coupled to the biodegradable polymers such that their controlled release would extend the oxygen scavenging abilities. Ascorbic acid can recycle tocopherol via TO^{\bullet} back to its effective antioxidant form of TOH producing an ascorbate radical, $Asc^{\bullet-}$. Ascorbic acid is then returned to its effective form through the reduction of the ascorbate radical via enzyme systems that use NADH and NADPH. Vitamin C and vitamin E are well suited for use in the present invention. Not only can they be efficiently recycled, their thermodynamic and kinetic properties make their radicals relatively harmless while being efficient antioxidants in small concentrations (Buettner, G. R. *Arch. Biochem. Biophys.* 300 (2): 535-543 (1993)).

B. Controlled Drug Delivery System

The present invention can be used as a controlled drug delivery system, providing sustained release of the antioxidant from the polymer matrix. The delivery system can be used to treat free radical associated disorders as well as decrease oxidative stress. In one embodiment, the antioxidant coupled to the biodegradable polymer can be a vitamin which acts as a biological antioxidant, including, but not limited to, β -carotene, vitamin A, vitamin C and vitamin E. These vitamins appear to work at different levels of carcinogenesis. (Stahelin *et al.*, *Am J Epidemiology* 133:766-775 (1991)). β -carotene may act as a scavenger for free radicals in the body. Vitamin A (retinol) has been recognized as being able to interfere with carcinogenesis. (See Goodman Gilman, *The Pharmacological Basis of Therapeutics*, Pergamon Press, New York (1990)). It is likely that vitamin A acts at the promotion or progression phase of carcinogenesis. Vitamin C (ascorbic acid) may also act as an antioxidant by preventing nitrosamine formation in the stomach and reducing fecal mutagenicity. Vitamin E (α -tocopherol), when acting as an antioxidant, may inhibit the formation of carcinogenic promoters by protecting essential cellular constituents, such as the polyunsaturated fatty acids of cell membranes, from peroxidation and by preventing the formation of toxic oxidation products. These and other physiologically acceptable antioxidants are within the scope of the invention. Also within the scope of the invention are combinations of antioxidants.

5

15

20

25

oils. The proper fluidity can be maintained, for example, by the use of a coating such as licithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the composition containing the antioxidant in the required amount in an appropriate solvent with one or a combination of ingredients identified above, as required. Generally, dispersions are prepared by incorporating the composition into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those identified above.

When the antioxidant-coupled polymer is suitably protected, as described above, the composition may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The composition and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration, the composition may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. The percentage of the compositions and preparations may, of course, be varied. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.

The tablets, troches, pills, capsules and the like may also contain a binder, an excipient, a lubricant, or a sweetening agent. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. As used herein "pharmaceutically acceptable carrier" includes any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the

like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in compositions of the invention is contemplated.

5 In another embodiment, a pharmaceutical agent or neutraceutical can be embedded in the antioxidant-coupled biodegradable polymer. In yet another embodiment, the antioxidant-coupled biodegradable polymer can be cast around or used to coat a pharmaceutical agent or neutraceutical. An oxygen sensitive pharmaceutical agent or neutraceutical will be protected from degradation and released in a sustained manner to a subject as described above.

10 It is especially advantageous to formulate compositions of the invention in dosage unit form for ease of administration and uniformity of dosage. "Dosage unit form" as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated. Each dosage contains a predetermined quantity of active compound calculated to produce the
15 desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention is dependent on the unique characteristics of the composition containing the antioxidant and the particular therapeutic effect to be achieved. Dosages are determined by reference to the usual dose and manner of administration of the ingredients.

20

IV. Uses

A. Controlled Delivery System

Many disorders or diseases arise due to oxidative stress and the presence of free radicals. The methods and compositions of the invention can be used to prevent, slow down or
25 treat disorders associated with antioxidant levels and excess free radicals. The present invention can be used to control the release of antioxidants into the body, which would be useful to maintain proper levels of antioxidants in the body. Antioxidants coupled to biodegradable polymers improve stability of the antioxidant as well as allow control over their release from the polymer. The coupled-antioxidant is present in an amount from 20% to about
30 80% (w/w) of the total composition. Non-limiting examples of disorders that arise due to altered levels of antioxidants include, aging at a higher than normal rate, segmental progeria

disorders, Down's syndrome; heart and cardiovascular diseases such as atherosclerosis, adriamycin cardiotoxicity, alcohol cardiomyopathy; gastrointestinal tract disorders such as inflammatory & immune injury, diabetes, pancreatitis, halogenated hydrocarbon liver injury; eye disorders such as cataractogenesis, degenerative retinal damage, macular degeneration; 5 kidney disorders such as autoimmune nephrotic syndromes and heavy metal nephrotoxicity; skin disorders such as solar radiation, thermal injury, porphyria; nervous system disorders such as hyperbaric oxygen, Parkinson's disease, neuronal ceroid lipofuscinoses, Alzheimer's disease, muscular dystrophy and multiple sclerosis; lung disorders such as lung cancer, oxidant pollutants (O_3 , NO_2), emphysema, bronchopulmonary dysphasia, asbestos carcinogenicity; red 10 blood cell disorder such as malaria Sick cell anemia, Fanconi's anemia and hemolytic anemia of prematurity; iron overload disorders such as idiopathic hemochromatosis, dietary iron overload and thalassemia; inflammatory-immune injury, for example, glomerulonephritis, autoimmune diseases, rheumatoid arthritis; ischemia reflow states disorders such as stroke and myocardial infarction; liver disorder such as alcohol-induced pathology and alcohol-induced 15 iron overload injury; and other oxidative stress disorders such as AIDS, radiation-induced injuries (accidental and radiotherapy), general low-grade inflammatory disorders, organ transplantation, inflamed rheumatoid joints and arrhythmias. The method of the invention can be used for treatment and/or prevention of a free radical induced disorder, or an oxidative stress disorder.

20

B. Food Packaging

Lipids in biological systems are highly susceptible to oxidation leading to deterioration. In food, lipid oxidation leads to rancidity, loss of nutritional value resulting from the destruction of vitamins (A, D, and E) and essential fatty acids, and the possible formation of toxic 25 compounds as well as flavor and color changes. Lipid oxidation is a major problem facing the meat industry. Rapid onset of rancidity in cooked meats during refrigerated storage, warmed over flavor, is detectable in 48 hours in cooked meats. Raw meat that had been ground and exposed to air rapidly develops warmed over flavor during refrigeration. The oxidative stability of meat is related to the degree of saturation of the lipid fraction, with chicken being most 30 susceptible, followed by pork, beef and lamb. Adding antioxidants directly to foodstuff is a

common method of food preservation. However, this method may have harmful side effects, such as allergies and accumulation of toxic levels of antioxidant. In an attempt to overcome the shortcomings of present food preservation techniques, a novel polymer containing covalently coupled functional antioxidants was invented. The invention can be used as packaging for foodstuff providing protection from oxygen degradation; moreover, the antioxidant will not leach out of the polymer and thus does not get absorbed into the body.

C. Biomedical

Cardiovascular disease including atherosclerosis is a common cause of death in chronic renal failure patients on long term hemodialysis. Such disease states have been linked to high levels of oxidative stress. A recent study of haemodialysis patients (Morena *et al. Nephrol. Dial. Transplant.* 17:422-427 (2002)) found that dialysis leads to a decrease in antioxidant defenses due to impaired enzyme activities and dramatically decreased plasma levels of ascorbic acid. Dialysis increases oxidative stress both through an increase in ROS production and a decrease in defense mechanisms, such as superoxide dismutase activity in erythrocytes and a decreased plasma glutathione peroxidase activity. In addition, many antioxidant vitamins get altered in uraemia. Therefore, ways to maintain or increase antioxidant levels, especially vitamin C which is known to be depleted through dialysis, are needed. The present invention can be used to slow or prevent the antioxidant depletion by coating the inside of the dialysis tubing with antioxidant coupled polymers. The antioxidant could be chosen from the group consisting of ascorbic acid, vitamin E derivatives, tocol, α -tocopherol, β -tocopherol, γ -tocopherol, ϕ -tocopherol, ϵ -tocopherol, ξ 1-tocopherol, ξ 2-tocopherol, η -tocopherol, vitamin B derivatives, thiamine, cyanocobalamin, ergocalciferol, cholecalciferol, vitamin K derivatives, phytonadione, menaquinone, quercetin, vitamin A derivatives, retinol, retinal, 3,4-didehydroretinol, α -carotene, β -carotene, δ -carotene, γ -carotene, cryptoxanthin, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, alpha-lipoic acid, glutathione, carotenoids, allylic sulfides, selegiline, N-acetylcysteine, lecithin, tartaric acid, caffeic acid, diaryl amines, thioethers, quinones, tannins, xanthenes, procyanidins, porphyrins, phenolphthalein, indophenol, coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof.

In a preferred embodiment, an ascorbic acid coupled polymer could coat the inside of a biomedical conduit, such as dialysis tubing or catheter. Ascorbic acid coupled polymers can have multiple benefits including decreasing ascorbic acid depletion and recycling vitamin E. Vitamin E is a well characterized peroxy scavenger that prevents lipid peroxidation. Its antioxidant function has been shown to depend on the presence of vitamin C. Alpha tocopherol is regenerated from tocopheroxyl radicals; thus, vitamins E can be maintained in its non-radical reduced form.

D. Manufacturing

Virtually all of the billions of pounds of thermoplastic resins used throughout the world each year require the addition of chemical stabilizers to protect them from heat, oxidation and mechanical stresses encountered in the conversion processes for fabricated products. Increased stabilization will be needed to protect these products from deterioration through their expected life. Antioxidants are used to permit processing of thermoplastics and to provide in-service protection of the converted products. In one embodiment, the present invention could be used to coat the inside of the vessels used in the manufacturing of the resins. In another embodiment, the methods of the present invention may be used to couple an antioxidant to the resins to directly protect from degradation and improve stability.

E. Topical Applications and Cosmetics

Photoaging, sagging skin and other signs of degenerative skin conditions, such as wrinkles and age spots are caused primarily by free radical damage. Vitamin C has been shown to accelerate wound healing, protect fatty tissues from oxidation damage, as well as play an integral role in collagen synthesis (Zhang *et al.*, *Bioelectrochem Bioenerg* 48:453-61 (1999)). Clinical studies show that antioxidants in a cosmetic vehicle can inhibit the induction of lipid peroxidation in stratum corneum lipids, which are produced endogenously or induced by UVB exposure (Pelle *et al.*, *Photodermatol Photoimmunol Photomed* 15:115-119 (1999)). α -Tocopherol has been shown to be the major antioxidant in the human stratum corneum. Depletion of α -tocopherol is an early and sensitive biomarker of environmentally induced oxidation. Topical and/or systemic application of antioxidants could support physiological mechanisms that maintain or restore a healthy skin barrier and protect the skin from

environmental stresses that may lead to UV-induced carcinogenesis, photoaging, or desquamatory skin disorders (Thiele *et al.*, *Curr Probl Dermatol* 29:26-42 (2001)).

5 The methods and compositions of the invention can be used to treat or protect from oxygen radicals that get produced by cells when exposed to UV light, injury, infection or drugs. In one embodiment, the antioxidant functionalized polymers can be used topically, such as an ointment, spray, cream, or lotion. In another embodiment, the release of antioxidants from the polymer matrix to the skin can be controlled. Antioxidants can be attached to the polymer such that a reaction that would cleave the antioxidant from the matrix can be controlled. Non-limiting
10 examples could include the use of a photosensitive reaction or light inducible enzymatic reaction catalyzed by a heat or light inducible enzyme that may be added to the topical composition.

In another embodiment, the present invention can be used in the topical treatment of viral lesions. Studies on mice and guinea pigs (Sheridan *et al.* *Antiviral Res.* 36: 157-166 (1997))
15 indicate that topical application of antioxidants, such as a formulation of vitamin E, sodium pyruvate and membrane stabilizing fatty acids may be useful in the reduction of the development, duration, and severity of lesions due to genital herpes simplex virus.

One or more physiologically acceptable antioxidants composition can be formulated in a
20 form suitable for topical application. For example, as a lotion, aqueous or aqueous-alcoholic gels, vesicle dispersions or as simple or complex emulsions (O/W, W/O, O/W/O or W/O/W emulsions), liquid, semi-liquid or solid consistency, such as milks, creams, gels, cream-gels, pastes and sticks, and can optionally be packaged as an aerosol and can be in the form of mousses or sprays. The composition can also be in a sunscreen. These compositions are
25 prepared according to the usual methods. The composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer. For example, a lotion or cream can be packaged in a bottle or a roll-ball applicator, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded
30 jar. The composition may also be included in capsules such as those described in U.S. Pat. No. 5,063,507.

A suitable dermatologically acceptable carrier must be chosen that is adequate for topical use, compatible with the coupled antioxidant, and will not add toxicity. An effective and safe carrier varies from about 50% to about 99% by weight of the compositions of the invention, preferably from about 75% to about 99%, and more preferably from about 85% to about 95%. The pharmaceutically acceptable excipient and biological or cosmetic agent to be used in conjunction with the present invention is dependent upon the intended use.

Antioxidants, which may be used in the present invention as anti-wrinkling and/or anti-aging agents may include, but are not limited to, retinoids (for example, retinoic acid, retinol, retinal, retinyl acetate, and retinyl palmitate) alpha hydroxy acids, galactose sugars (for example, melibiose and lactose), antioxidants, including but not limited to water soluble antioxidants such as sulfhydryl compounds and their derivatives (for example, sodium metabisulfite and N-acetyl-cysteine, acetyl-cysteine), lipoic acid and dihydrolipoic acid, resveratrol, lactoferin, ascorbic acid and ascorbic acid derivatives (for example ascorbyl palmitate and ascorbyl polypeptide). Oil soluble antioxidants suitable for use in the compositions of this invention include, but are not limited to tocopherols (for example, tocopheryl acetate, alpha-tocopherol), tocotrienols and ubiquinone. Antioxidants isolated from natural extracts are suitable for use in this invention. These include, but are not limited to, flavonoids, phenolic compounds, flavones, flavanones, isoflavonoids, mono, di- and tri-terpenes, sterols and their derivatives. Flavonoids are a major source of plant phenols that have demonstrated antioxidant capabilities. Rosemary contains a number of compounds possessing antioxidant activity, such as carnosol, rosmanol, rosmariquinone, and rosmaridiphenol. Other sources of these compounds include grape seed, green tea, pine bark and propolis extracts and legume extracts and the like.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application, are incorporated herein by reference.

Examples

Example 1: Materials and Methods

(i) Materials

5

Horseradish peroxidase (Type II, 150-200 units/ mg solid) and hydrogen peroxide (30% w/w) were purchased from Sigma Chemical Co., St. Louis, MO. 4-Vinyl benzoic acid, trifluoroethanol, N,N-dimethylaminopyridine, dicyclohexyldicarbodiimide, tetrahydrofuran, dioxane, L-ascorbic acid, triethylamine, 2,2-diphenyl-1-picryl hydrazyl radical (DPPH•) and 2,6-di-
 10 di-tert-butyl-4-methylphenol were purchased from Aldrich Chemical Co., Milwaukee, WI. Solvents used were high performance liquid chromatography grade and purchased from Fischer Scientific Co., Pittsburg, PA. *Candida antarctica* lipase, immobilized, was a gift from NovoNordisk Co.

15

¹H NMR and ¹³C NMR spectra were recorded using a Bruker DPX 300 spectrometer. Chemical shifts in parts per million (ppm) were referenced relative to tetramethylsilane (TMS, 0.00 ppm) as internal reference.

(ii) Synthesis of trifluoroethyl 4-vinylbenzoate

20

p-Vinylbenzoic acid (1) (5.0g, 33.74 mM), trifluoroethanol (4.9 mL, 67.48 mM), 4-(dimethylamino) pyridine (4.968g, 40.49 mM) and 1,3-dicyclohexylcarbodiimide (DCCI, 8.355g, 40.49 mM) were stirred in 100mL tetrahydrofuran at 25°C for 24 hours. 75 mg of 2,6-di-tert-butyl-4-methylphenol was added to the reaction mixture to avoid vinyl polymerization during solvent evaporation. Reaction was monitored by silica gel thin layer chromatography.

25

Crude product was purified using silica gel column chromatography with eluent consisting of chloroform:hexane in 15: 85 ratio. Trifluoroethyl 4-vinylbenzoate (2) was isolated in 94% yield and analyzed by NMR: ¹H NMR (CDCl₃): 4.68 (2H, q, -CH₂-CF₃), 5.40 (1H, d, J=10 Hz, -CH=CH₂), 5.87(1H, d, J=17 Hz, -CH=CH₂), 6.74(1H, dd, J=10Hz, 12Hz, -CH=CH₂), 7.46 (2H, m, aromatic protons), and 8.02 (2H, m, aromatic protons). ¹³C NMR (CDCl₃): 24.8, 25.6, 30.4,

30

35.1(-CH₂CF₃), 60.1, 60.6, 61.1, 61.6 (-C H₂-CF₃), 117.2 (-CH=C H₂), 135.9 (-C H=CH₂), 126.4, 127.6, 130.5, 143.0 (aromatic carbons), and 164.8 (-C=O).

Example 2. Enzymatic Coupling of Ascorbic Acid to a Vinyl Monomer: Synthesis L- ascorbyl 4-vinylbenzoate (3)

The possible chemical pathway which results in major degradation products involves the primary hydroxyl group of ascorbic acid. The primary hydroxyl group was regioselectively protected via mild enzyme catalysed transesterification reaction which stops degradation and an active ascorbic acid was attached to the vinyl monomer (Figure 1). This synthesis can be done as follows:

Immobilized *Candida antarctica* lipase and L-ascorbic acid were dried under high vacuum in a desiccator with phosphorous pentoxide for 24 hours prior to reaction. The reaction approach was an enzymatic transesterification where the primary hydroxyl group of ascorbic acid is regioselectively acylated by trifluoroethyl 4-vinylbenzoate (2) via the acyl enzyme complex. In a typical reaction, L-ascorbic acid (2.0g, 11.35 mM), trifluoroethyl 4-vinylbenzoate (2) (2.611g, 11.35 mM), *Candida antarctica* lipase (10g, immobilized) were stirred in 40 mL of anhydrous dioxane at 60°C. 75mg of 2,6-di-tert-butyl-4-methylphenol was added to the reaction mixture to avoid vinyl polymerization at 60°C and during solvent evaporation. Reactions were monitored by thin layer chromatography. Enzyme was filtered, washed thoroughly with dioxane and solvent was evaporated by rotary evaporation under reduced pressure. NMR was performed to confirm the presence of the reaction product, L- ascorbyl 4-vinylbenzoate (3). ¹H NMR (CD₃OD): 4.27 (1H, m, -CH-OH), 4.46 (2H, m, -CH₂-O), 4.85(1H, d, -CH-O), 5.39 (1H, d, J=10Hz, -CH=CH₂), 5.93 (1H, d, J=9 Hz, -CH=CH₂), 6.80 (1H, dd, J=10Hz & 10Hz, -CH=CH₂), 7.54 and 8.02 (aromatic protons). ¹³C NMR (CD₃OD): 63.6(-CH₂-O), 68.2 (CH-OH), 76.9 (C H-O), 117.2 (CH=CH₂), 120.2 (=C-OH), 137.3 (CH=CH₂), 127.3, 130.2, 131.1, 143.8 (aromatic protons), 154.8 (=C-OH), 167.6 (Ar-C=O(O)), 173.6(-C=O(O)). In the ¹H-NMR spectrum of L-ascorbyl 4-vinyl benzoate (3), C-6H (methylene protons) appeared at δ 4.47 which otherwise appeared at δ 3.68 in ascorbic acid. This downfield shift indicated the formation of an ester involving the C-6-OH group. In addition the integral ratio of vinyl phenyl protons and ascorbic acid corresponded to a mono acylated product. In the ¹³C-NMR spectrum of L-ascorbyl 4-vinylbenzoate (3), the C-6, methylene carbon appeared at δ 77.45 which otherwise appeared at 63.60 in ascorbic acid, indicating ester formation with C-6-O. No significant shift was observed in the C-2, C-3, or C-5 carbons. Furthermore, the study of integral values of

¹H-NMR signals, as well as peak positions in proton and carbon NMR, confirmed that the expected product was formed.


Example 3. Enzymatic Polymerization of L-ascorbyl 4-vinylbenzoate (3)

5 The vinyl monomer functionalized with ascorbic acid was polymerized with horseradish peroxidase using initiator 2,4-pentanedione and oxidant hydrogen peroxide in 50:50 water and methanol. 2,4-Pentanedione was distilled under vacuum before use. In a general procedure, 1.8 mL water, 2.0 mL methanol were flushed with nitrogen for 10 min. L-ascorbyl 4-vinylbenzoate (3) (457 mg, 1.5 mM) was added to the reaction mixture. Horseradish peroxidase (3.56×10^{-4} 10 mM, 2400 units, 16 mg) was dissolved in 200 μ L of water. Hydrogen peroxide, 0.15 mM (17 μ L), and 0.30 mM of 2,4-pentanedione were added simultaneously after the addition of the enzyme. Polymerization was conducted for 24 h with continuous stirring. The reaction mixture was poured into 200 mL methanol. No solid product was obtained. The polymer was soluble in excess of methanol. The excess methanol was evaporated and the crude product was washed 15 with acetone to remove the unpolymerized monomer. The product, polymerized L- ascorbyl 4-vinylbenzoate (4), was dried under vacuum and analyzed by NMR (Figure 2) and MALDI-TOF mass spectrum (Figure 3). The ¹H-NMR spectrum of polymerized L-ascorbyl 4-vinylbenzoate (4) (Figure 2) showed the presence of methylene and methine protons at δ 0.85 to 2.75 and an absence of vinyl protons at δ 5.39, 5.93, & 6.80, indicating successful vinyl polymerization. 20 Aromatic protons appear as broad singlets at δ 6.60 & 7.63. Furthermore the presence of C-5 and C-6 protons at δ 4.13 to 4.63 confirmed that the vinyl group was polymerized and ascorbic acid was attached as pendent group through a C-6-O linkage. MALDI-TOF MS (Figure 3) showed a polymer with $M_n = 1225$ ($ds = 1$, $DP = 4$), $PD = 1.03$. In a separate experiment, the soluble fraction of the polymer with $M_w = 7000$ was analyzed by MALDI-TOF. The 25 product containing the higher molecular weight fraction (above M_w 7000) was also analyzed by MALDI-TOF, but due to lack of solubility could not be fully assessed. This solution behavior suggests significantly higher molecular weight than 7,000 Da, and based on film forming behavior, further supports this assessment.

30

Example 4. Scavenging effect of Polymerized L-ascorbyl 4-vinylbenzoate (4) on DPPH•

The antioxidant activity of polymer L-ascorbyl 4-vinylbenzoate (4) and ascorbic acid were compared by measuring their scavenging effect on 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals using known methods (Chen et al. *J. Agric. Food Chem.* 47, 2226-2228 (1999); (Duh et al. *J. Agric. Food Chem.* 49, 1455-14 (2001)). Antioxidant activity can be measured in terms of radical scavenging, according to DPPH radical method as detailed by the equation below.



- 10 The reduction of DPPH• by the ascorbyl-coupled polymer results in the decrease of the optical absorbance at 514 nm of the purple-blue colored solution of DPPH• in methanol. Test compound and DPPH (final conc. 0.2 mM) pre-dissolved in methanol were thoroughly mixed and the solution were kept at room temperature in dark for 30 min. Thereafter the absorbance of the samples was measured using a spectrophotometer (HP 8452, diode Array Spectrophotometer, MS-DOS UV/VIS) at 514 nm. Methanol without DPPH was used as reference. Up to 238 µM conc. poly(L-ascorbyl 4-vinylbenzoate) fully scavenged the DPPH radical. Each sample was run in triplicate, and the values were averaged (Table 1).

Table 1: Scavenging effect of polymer of L-ascorbyl 4-vinylbenzoate (4) on DPPH.

Rx. No.	Compound	Concentration (µM)	Absorbance at 514 nm ^a
1.	DPPH (blank)	---	1.12 ± 0.01
2.	Ascorbic acid	329 ^b	--- ^c
3.	Ascorbic acid	187 ^b	---
4.	Ascorbic acid	91 ^b	0.12 ± 0.01
5.	Polymer	663	---
6.	Polymer	330	---
7.	Polymer	238	---
8.	Polymer	189	1.0 ± 0.00
9.	Polymer	132	1.39 ± 0.01
10.	Polymer	91	1.67 ± 0.01
11.	Polymer	58	1.87 ± 0.01

20 ^a reactions were performed in triplicate; average ± standard deviation.

^bamount of ascorbic acid used instead of polymer.

^cindicates all DHHP scavenged by compound.

Example 5. Enzymatic Polymerization of L-Ascorbyl 4-hydroxy phenyl acetate (7) following Enzymatic Coupling of Ascorbic Acid to Trifluoroethyl-4-Hydroxyphenyl Acetate (6)

The enzymatic coupling of ascorbic acid to an aromatic phenolic monomer followed by enzymatic polymerization is shown in this Example.

(i) Synthesis of Trifluoroethyl 4-hydroxyphenyl acetate (6)

As illustrated in Figure 4, p-hydroxyphenylacetic acid (5) (15g, 0.099 mol), trifluoroethanol (15 mL, 0.197 mol), 1,3-dicyclohexylcarbodiimide (24.4g, 0.118 mol), and 4-(dimethylamino) pyridine (14.45 g, 0.118 mol) were stirred at 25°C for 24 hours. The reaction was monitored by silica gel thin layer column chromatography. The crude product was purified using silica gel column chromatography with the eluent consisting of ethylacetate: petroleum ether in 25:75 ratio. Trifluoroethyl 4-hydroxyphenyl acetate (6) was isolated in 60% yield and analyzed by NMR. ¹H NMR (CDCl₃): δ 3.64 (2H, s, C-7H), δ 4.45 (2H, q, -CH₂-CF₃), δ 6.75 (2H, d, ArH), δ 7.10 (2H, d, ArH). ¹³C NMR (CDCl₃): δ 39.82 (C-7), δ 60.85 (-CH₂CF₃), 115.87 (C-2 & C-6), 124.87 (C-4), 130.69 (C-3 & C-5), 155.27 (C-1), and 171.19 (C-8).

(ii) Enzymatic Coupling of Ascorbic Acid to a Phenolic Monomer: Synthesis of L-ascorbyl 4-hydroxyphenyl acetate (7)

In a typical reaction, L-ascorbic acid (5.39 g, 0.030 mol), trifluoroethyl 4-hydroxyphenyl acetate (6) (10.733 g, 0.046 mol), *Candida antarctica* lipase (10 g, immobilized) were stirred in 100 mL of anhydrous dioxane at 60°C for 24 hours as shown schematically in Figure 4. Reactions were monitored by thin layer chromatography using solvent system methanol:chloroform in 1:1 ratio. The enzyme was filtered out, the product washed thoroughly with dioxane and solvent was evaporated by rotary evaporation under reduced pressure. The product, L-ascorbyl 4-hydroxyphenyl acetate (7), was isolated in 96% yield and analyzed by NMR. ¹H NMR (CD₃OD): δ 3.64 (2H, s, C-7H), δ 4.08 (1H, m, C-5'H), δ 4.22 (2H, m, C-6'H), δ 4.66 (1H, d, C-4'H), δ 6.74 (2H, m, ArH), and δ 7.09 (2H, m, ArH). ¹³C NMR (CD₃OD): δ 40.97 (C-7), δ 63.65, 68.17 (C-4' & C-5'), δ 77.21 (C-6'), δ 116.37 (C-2 & C-6), δ 120.11 (C-2'), δ 126.29 (C-4), δ 131.50 (C-3 & C-5), δ 154.16 (C-3'), δ 157.57 (C-1), δ 173.82, 173.25 (C-1' & C-8).

(iii) Enzymatic Polymerization of L-ascorbyl 4-hydroxyphenyl acetate (7): Synthesis of Polymerized L-ascorbyl 4-hydroxyphenyl acetate (8)

The phenolic monomer functionalized with ascorbic acid (7) can be polymerized with horseradish peroxidase using initiator 2,4-pentanedione and oxidant hydrogen peroxide in 50:50 water and methanol. 2,4-Pentanedione can be distilled under vacuum before use. In a general procedure, water and methanol can be flushed with nitrogen. L-ascorbyl 4-hydroxyphenyl acetate (7) can be added to the reaction mixture. Horseradish peroxidase can be dissolved in 200 μ L of water. Hydrogen peroxide and 2,4-pentanedione can be simultaneously after the addition of the enzyme. Polymerization can be conducted for 24 h with continuous stirring. The reaction mixture can be poured into methanol. The excess methanol can be evaporated and the crude product can be washed with acetone to remove the unpolymerized monomer. The product, polymerized L- ascorbyl 4-hydroxyphenyl acetate (7), can be dried under vacuum.

Example 6. Enzymatic Polymerization of Retinol and Tocol Functionalized Monomers.

The following Example illustrates that the methods of this invention can be used to enzymatically polymerize a variety of antioxidants, such as retinol (Vitamin A) and tocol (Vitamin E), which have been coupled to monomers.

(i) Enzymatic Polymerization of Retinol Coupled Vinyl Monomers: Synthesis of Polymerized Retinyl 4-Vinylbenzoate (11)

As illustrated in Figure 5, retinyl 4-vinylbenzoate (10) was synthesized from p-vinylbenzoic acid (9) (310 mg, 2.09 mM), retinol (500mg, 1.75 mM), 4-(dimethylamino) pyridine (320 mg, 2.62 mM) and 1,3-dicyclohexylcarbodiimide (DCC, 540 mg, 2.62mM). The substrates was stirred in 50 mL tetrahydrofuran at 25°C for 24 hours. 50 mg of 2,6-di-tert-butyl-4- methylphenol was added to the reaction mixture to avoid vinyl polymerization during solvent evaporation. The reaction was monitored by silica gel thin layer chromatography. Crude product was purified using silica gel column chromatography. The product, retinyl 4-vinylbenzoate (10), can be analyzed by NMR. In addition, known methods of hydroxyl coupling with acid groups can be used to produce retinyl 4-vinylbenzoate (10), such as the synthesis methods described in Zhao et al. *J. Org. Chem.* 2000, 65, 2933-2938; Langer et al. *Macromolecules* 1999, 32, 3658-3662; and Calmes et al. *Tetrahedron Asymmetry* 2000, 11, 737-741.

Retinyl 4-vinylbenzoate (10) can be polymerized to form (11) using enzyme horseradish peroxidase, oxidant hydrogen peroxide and initiator 2,4-pentanedione using the protocol described above in Example 3.

5 **(ii) Enzymatic Polymerization of Retinol Coupled Phenolic Monomers: Synthesis of Polymerized Retinyl 4-Hydroxybenzylacetate (15)**

As illustrated in Example 6, retinyl 4-hydroxybenzylacetate (14) can be synthesized from 4 hydroxyphenylacetic acid (265 mg, 1.75 mM), retinol (500mg, 1.75 mM), 4-(dimethylamino) pyridine (255 mg, 2.09 mM) and 1,3-dicyclohexylcarbodiimide (DCC, 432 mg, 2.09mM). The
10 reaction can be stirred in 50 mL tetrahydrofuran at 25°C for 24 hours and monitored by silica gel thin layer chromatography. The crude product can be purified using silica gel column chromatography. In addition, known methods of hydroxyl coupling with acid groups can be used to produce retinyl 4-hydroxybenzylacetate (14), such as the synthesis methods described in Zhao et al. *J. Org. Chem.* 2000, 65, 2933-2938; Langer et al. *Macromolecules* 1999, 32, 3658-
15 3662; and Calmes et al. *Tetrahedron Asymmetry* 2000, 11, 737-741.

Retinyl 4-hydroxybenzylacetate (14) can be polymerized to form (15) using enzyme horseradish peroxidase and oxidant hydrogen peroxide using the protocols described in Example 5(iii).

20 **(iii) Enzymatic Polymerization of Tocol Coupled Vinyl Monomers: Synthesis of Polymerized 2-Methyl-2-(4, 8, 12-trimethyltridecyl)-6-(4-vinylbenzoyl)-chromanol (20)**

The steps of this Example are illustrated in Figure 7. The first step is the production of tocol [2-Methyl-2-(4, 8, 12-trimethyltridecyl)-6-chromanol] (18). Tocol [2-Methyl-2-(4, 8, 12-
25 trimethyltridecyl)-6-chromanol] (18) was produced using hydroquinone (16) (4.4 g, 39.86 mmol), phytol (17) (11.8 g, 39.79 mmol), formic acid (60 mL) and dry benzene (60 mL) refluxed under nitrogen atmosphere for five hours. The benzene layer was separated using separating funnel. The acid layer was extracted five times with (5x 50 mL) benzene and the combined benzene solution was dried over sodium sulfate (anhydrous) and vacuum distilled.
30 Removal of solvent left a light brown oil. The crude product gave a mixture of five compounds (by silica-gel thin layer chromatography) which was purified by silica-gel column

chromatography using eluent chloroform:petroleum ether in 30:70 ratio. The purified compound, tocol [2-Methyl-2-(4, 8, 12-trimethyltridecyl)-6-chromanol] (18), was characterized by ^1H and ^{13}C NMR. ^1H NMR (CDCl_3): δ 0.85 (12H, m, C-13', C-15', C-16', & C-17'), δ 1.0 – 1.90 (14H, 4m, C-3H, C-2'H to C-12'H & C-14'H), δ 2.70 (2H, t, C-4H), δ 6.70 (3H, m, C-5H, C-7H & C-8H). ^{13}C NMR (CDCl_3): δ 19.86, 19.93, 21.28, 22.48, 22.82, 22.92, 24.25, 24.63, 24.98 (C-2', C-6', C-10', C-13', C-14', C-15', C-16', C-17'), δ 28.14, 32.86, 32.87, 32.94, 37.44, 37.56, 39.53 (C-1', C-3', C-4', C-5', C-7', C-8', C-9', C-11', C-12'), δ 76.27 (C-2), 114.76 (C-5), 115.72 (C-7), 117.94 (C-8), 122.19 (C-10), 147.76, 148.71 (C-6 & C-9).

10

The second step is functionalizing the vinyl monomers with the antioxidant tocol (18) to form 2-methyl-2-(4, 8, 12-trimethyltridecyl)-6-(4-vinylbenzoyl)-chromanol (19). p-Vinylbenzoic acid (763 mg, 5.15 mM), tocol (1.8 g, 4.64 mM), 4-(dimethylamino) pyridine (940 mg, 7.7 mM) and 1,3-dicyclohexylcarbodiimide (DCC, 1.594g, 7.7 mM) were stirred in 50 mL tetrahydrofuran at 25°C for 24 hours. 50 mg of 2,6-di-tert-butyl-4-methylphenol was added to the reaction mixture to avoid vinyl polymerization during solvent evaporation. The reaction was monitored by silica gel thin layer chromatography. The crude product was purified using silica gel column chromatography with eluent consisting of chloroform:petroleum ether in 30: 70 ratio. The product, 2-methyl-2-(4, 8, 12-trimethyltridecyl)-6-(4-vinylbenzoyl)-chromanol (19), was isolated in 78% yield. ^1H NMR (CDCl_3): δ 0.85 (12H, m, C-13', C-15', C-16', & C-17'), δ 1.0 – 1.90 (14H, 4m, C-1'H to C-12'H & C-14'H), δ 2.70 (2H, t, C-4H), δ 5.40 (1H, d, C-1''H), δ 5.89 (1H, d, C-2''H), δ 6.80 (4H, m, C-1''H, C-5H, C-7H & C-8H), δ 7.50 (2H, d, C-4''H & C-8''H), δ 8.13 (2H, d, C-5''H & C-7''H). ^{13}C NMR (CDCl_3): δ 19.83, 19.90, 19.97, 21.26, 22.26, 22.54, 22.93, 24.42, 24.67, 25.01 (C-2', C-6', C-10', C-13', C-14', C-15', C-16', C-17'), δ 28.18, 30.83, 32.93, 32.98, 37.50, 37.60, 37.65, 37.76, 39.59, 40.19, 40.24 (C-1', C-3', C-4', C-5', C-7', C-8', C-9', C-11', C-12'), 76.67 (C-2), 116.97 (C-1''), 118.05, 120.56, 122.11 (C-5, C-7, & C-8), 126.43 (C-4'' & C-8''), 129.13 (C-10), 130.62 (C-5'' & C-7''), 136.20 (C-2''), 142.62, 143.61 (C-9, C-6''), 151.98 (C-6), 165.60 (C-9'').

25

The compound 2-methyl-2-(4, 8, 12-trimethyltridecyl)-6-(4-vinylbenzoyl)-chromanol can be polymerized to form (20) using enzyme horseradish peroxidase in the presence of hydrogen peroxide and 2,4-pentanedione using the protocols in Example 5(iii) .

5

What is claimed is:

1. A method for enzymatically synthesizing a functionalized polymer comprising:
coupling an antioxidant to each of a plurality of monomers; and,
enzymatically polymerizing the antioxidant-coupled monomers to form an
antioxidant-coupled functionalized polymer;
5 whereby the resultant functionalized polymer has inherent antioxidant capabilities.
2. The method of claim 1, wherein the step of coupling an antioxidant to each of a plurality
of monomers is carried out such that the resultant polymer has at least 1% of its monomeric units
functionalized with antioxidants.
10
3. The method of claim 1, wherein the step of coupling an antioxidant to each of a plurality
of monomers is carried out such that the resultant polymer has at least 10% of its monomeric
units functionalized with antioxidants.
- 15 4. The method of claim 1, wherein the method further comprises coupling at least one
antioxidant per monomer.
5. The method of claim 1, wherein the method further comprises selecting a monomer from
the group consisting of vinylbenzoic acid, amino acids, amino acid derivatives, carbohydrates,
20 lactones, lactides, cyclic carbonates, esters, olefins, amides, urethanes, acrylides, vinyl
monomers, vinyl ethers, acetals, aryl sulfones, ether sulfones, imides, etherketones, phenylene
oxides, phenylene sulfides, carbonates, epoxides, phenolics, aminoplasts, sophorolactones,
nucleosides, and dendrimers.
- 25 6. The method of claim 1, wherein the step of coupling an antioxidant to each of a plurality
of monomers further comprises using an enzyme.
7. The method of claim 6, wherein the step of coupling an antioxidant to each of a plurality
of monomers further comprises selectively acylating primary hydroxyl groups.
30

8. The method of claim 6, wherein the method further comprises enzymatically coupling a primary hydroxyl group of the antioxidant to the monomer.
9. The method of claim 6, wherein the step of enzymatically coupling an antioxidant to each of a plurality of monomers further comprises selecting an enzyme from the group consisting of proteases, glycosidases, and lipases.
10. The method of claim 6, wherein the method further comprises utilizing *Candida antarctica* lipase.
11. The method of claim 1, wherein the method further comprises selecting the antioxidant from the group consisting of ascorbic acids, vitamin E derivatives, tocopherols, α -tocopherols, β -tocopherols, γ -tocopherols, ϕ -tocopherols, ϵ -tocopherols, ξ 1-tocopherols, ξ 2-tocopherols, η -tocopherols, vitamin B derivatives, thiamines, cyanocobalamins, ergocalciferols, cholecalciferols, vitamin K derivatives, phytonadiones, menaquinones, quercetins, vitamin A derivatives, retinols, retinals, 3,4-didehydroretinols, α -carotenes, β -carotenes, δ -carotenes, γ -carotenes, cryptoxanthins, citric acid, butylated hydroxyanisoles, butylated hydroxytoluenes, alpha-lipoic acids, glutathiones, carotenoids, allylic sulfides, selegilines, N-actylcysteines, lecithins, tartaric acids, caffeic acids, diaryl amines, thioethers, quinones, tannins, xanthenes, procyanidins, porphyrins, phenolphthaleins, indophenol, coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof.
12. The method of claim 1, wherein the method of enzymatically polymerizing the antioxidant-coupled monomers further comprises using horseradish peroxidase (HRP).
13. The method of claim 1, wherein the method further comprises casting the polymer into a shaped form.
14. The method of claim 13, wherein the form is selected from the group consisting of films, fibers, coatings, sheets, tubes and combinations thereof.

15. The method of claim 1, wherein the method further comprises selecting a monomer that is biodegradable.
16. The method of claim 1, wherein the method further comprises selecting biodegradable monomers from the group consisting of polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids, "pseudo" amino acids, esteramides, anhydrides, orthoesters, sophorolactones, nucleosides, dendrimers, and combinations thereof.
17. The method of claim 1, wherein the method further comprises selecting a single type of monomer and the step of polymerizing the antioxidant-coupled monomers into an antioxidant-coupled polymer further comprises forming an antioxidant-coupled homopolymer.
18. The method of claim 1, wherein the method further comprises selecting a plurality of different monomers and the step of polymerizing the antioxidant-coupled monomers into an antioxidant-coupled polymer further comprises forming an antioxidant-coupled copolymer.
19. A method of protecting an oxygen sensitive material from degradation comprising:
coupling an antioxidant to each of a plurality of monomers;
enzymatically polymerizing the antioxidant-coupled monomers to form an antioxidant-coupled polymer; and,
surrounding the material within the antioxidant-coupled polymer,
whereby the antioxidant-coupled polymer scavenges free radicals so as to protect material from oxygen degradation.
20. The method of claim 19, wherein the step of coupling an antioxidant to each of a plurality of monomers further comprises selecting monomers from the group consisting of vinylbenzoic acid, amino acids, amino acid derivatives, carbohydrates, lactones, lactides, cyclic carbonates, esters, olefins, amides, urethanes, acrylides, vinyl monomers, vinyl ethers, acetals, aryl sulfones, ether sulfones, imides, etherketones, phenylene oxides, phenylene sulfides, carbonates, epoxides, phenolics, aminoplasts, sophorolactones, nucleosides, and dendrimers.

21. The method of claim 19, wherein the step of coupling an antioxidant to each of a plurality of monomers further comprises selecting antioxidants from the group consisting of ascorbic acid, vitamin E derivatives, tocol, α -tocopherol, β -tocopherol, γ -tocopherol, ϕ -tocopherol, ϵ -
5 tocopherol, ξ 1-tocopherol, ξ 2-tocopherol, η -tocopherol, vitamin B derivatives, thiamine, cyanocobalamin, ergocalciferol, cholecalciferol, vitamin K derivatives, phytonadione, menaquinone, quercetin, vitamin A derivatives, retinol, retinal, 3,4-didehydroretinol, α -carotene, β -carotene, δ -carotene, γ -carotene, cryptoxanthin, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, tartaric acid, caffeic acid, diaryl amines, thioethers, quinones,
10 porphrins, phenolphthalein, indophenol, coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof.
22. The method of claim 19, wherein the step of coupling an antioxidant to each of a plurality of monomers further comprises coupling ascorbic acid to the monomers.
15
23. The method of claim 19, wherein the step of coupling an antioxidant to each of a plurality of monomers further comprises using an enzyme.
24. The method of claim 23, wherein the method further comprises selecting the enzyme
20 from the group consisting of proteases, glycosidases, and lipases.
25. The method of claim 23, wherein the method further comprises selectively acylating a primary hydroxyl group of the antioxidant.
- 25 26. The method of claim 23, wherein the step of enzymatically coupling an antioxidant to each of a plurality of monomers further comprises utilizing *Candida antarctica* lipase.
27. The method of claim 19, wherein the step of enzymatically polymerizing the antioxidant-coupled monomers further comprises using horseradish peroxidase (HRP).
30

28. The method of claim 19, wherein the method further comprises casting the antioxidant-coupled polymer into a shaped form selected from the group consisting of a film, a fiber, a coating, a sheet, and combinations thereof.
- 5 29. The method of claim 28, wherein the method further comprises housing oxygen sensitive material in direct contact with the shaped form.
30. The method of claim 19, wherein the method further comprises forming a packaging for foodstuff, wherein the antioxidant coupled polymer is in direct contact with the foodstuff.
- 10 31. The method of claim 19, wherein the method further comprises coating a pharmaceutical agent with the antioxidant coupled polymer.
32. The method of claim 19, wherein the method further comprises applying a second oxygen
15 impermeable packaging material coating the antioxidant coupled polymer, distal to the oxygen sensitive material.
33. The method of claim 19, wherein the step of polymerizing the antioxidant-coupled monomers into an antioxidant-coupled polymer further comprises forming a homopolymer.
- 20 34. The method of claim 19, wherein the step of polymerizing the antioxidant-coupled monomers into an antioxidant-coupled polymer further comprises forming a copolymer.
35. The method of claim 19, wherein the method further comprises casting the antioxidant-
25 coupled polymer into a conduit for oxygen sensitive material wherein the oxygen sensitive material is in direct contact with the antioxidant coupled polymer.
36. The method of claim 19, wherein the method further comprises embedding the material
30 within the antioxidant-coupled polymer.

37. The method of claim 19, wherein the method further comprises casting the polymer around the material.

38. The method of claim 19, wherein the method further comprises utilizing biodegradable
5 monomers.

39. The method of claim 38, wherein the method further comprises selecting biodegradable monomers from the group consisting of polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids,
10 "pseudo" amino acids, esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, biodegradable dendrimers, and combinations thereof.

40. The method of claim 19 or 38, wherein the method further comprises implanting the antioxidant-coupled polymer into a subject.

15

41. A medical device having at least one surface coated with a polymer comprising monomeric units functionalized with antioxidants, the polymer formed by coupling the antioxidants to each of a plurality of monomeric units to form antioxidant-coupled monomeric units and enzymatically polymerizing the antioxidant-coupled monomeric units,

20

whereby the polymer coated medical device scavenges free radicals so as to protect oxygen sensitive materials from oxygen degradation.

25

42. The medical device of claim 41, wherein the medical device is an implantable medical device selected from the group consisting of dialysis apparatus, stents, filtration apparatus, catheters, sutures, tubings, syringes, endoscopes, and prostheses.

43. The medical device of claim 41, wherein the antioxidant functionalized polymer coats a medical device, such that the antioxidant-coupled polymer is in direct contact with oxygen sensitive materials.

30

44. The medical device of claim 41, wherein the monomeric units are selected from the group consisting of vinylbenzoic acid, amino acids, amino acid derivatives, carbohydrates, lactones, lactides, cyclic carbonates, esters, olefins, amides, urethanes, acrylides, vinyl monomers, vinyl ethers, acetals, aryl sulfones, ether sulfones, imides, etherketones, phenylene oxides, phenylene sulfides, carbonates, epoxides, phenolics, aminoplasts, saphorolactones, nucleosides, dendrimers, and combinations thereof.
45. The medical device of claim 41, wherein the antioxidants are selected from the group consisting of ascorbic acid, vitamin E derivatives, tocol, α -tocopherol, β -tocopherol, γ -tocopherol, ϕ -tocopherol, ϵ -tocopherol, ξ 1-tocopherol, ξ 2-tocopherol, η -tocopherol, vitamin B derivatives, thiamine, cyanocobalamin, ergocalciferol, cholecalciferol, vitamin K derivatives, phytonadione, menaquinone, quercetin, vitamin A derivatives, retinol, retinal, 3,4-didehydroretinol, α -carotene, β -carotene, δ -carotene, γ -carotene, cryptoxanthin, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, tartaric acid, caffeic acid, diaryl amines, thioethers, quinones, porphyrins, phenolphthalein, indophenol, coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof.
46. The medical device of claim 41, wherein a second oxygen impermeable material coats the antioxidant-coupled polymer, distal to the oxygen sensitive material.
47. The medical device of claim 41, wherein the monomeric units are biodegradable monomers.
48. The medical device of claim 47, wherein the biodegradable monomers are selected from the group consisting of polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids, "pseudo" amino acids, esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, biodegradable dendrimers, and combinations thereof.
49. The medical device of claim 41, wherein at least 1% of its monomeric units are functionalized with antioxidants.

50. The medical device of claim 41, wherein at least 10% of its monomeric units are functionalized with antioxidants.
- 5 51. The medical device of claim 41, wherein at least one antioxidant is coupled per monomeric unit.
52. The medical device of claim 41, wherein an enzyme is used to couple an antioxidant to the monomeric units.
- 10 53. The medical device of claim 41, wherein at least one enzyme is used to polymerize the functionalized monomeric units.
54. An antioxidant coupled packaging material comprising,
15 a first film layer cast from a polymer with monomeric units functionalized with an antioxidant, the polymer formed by coupling the antioxidant to each of a plurality of monomeric units to form antioxidant-coupled monomeric units and enzymatically polymerizing the antioxidant-coupled monomeric units; and,
a second barrier film layer,
20 such that the first layer encases a material and the second layer is oxygen impermeable.
55. The antioxidant coupled packaging material of claim 54, wherein the first layer is in direct contact with oxygen sensitive materials.
- 25 56. The antioxidant coupled packaging material of claim 54, wherein the first layer has at least 1% of its monomeric units functionalized with antioxidants.
57. The antioxidant coupled packaging material of claim 54, wherein the first layer has at least 10% of its monomeric units functionalized with antioxidants.
- 30

58. The antioxidant coupled packaging material of claim 54, wherein the first layer has at least one antioxidant per monomeric unit.
59. The antioxidant coupled packaging material of claim 54, wherein the monomeric units are selected from the group consisting of vinylbenzoic acid, amino acids, amino acid derivatives, carbohydrates, lactones, lactides, cyclic carbonates, esters, olefins, amides, urethanes, acrylides, vinyl monomers, vinyl ethers, acetals, aryl sulfones, ether sulfones, imides, etherketones, phenylene oxides, phenylene sulfides, carbonates, epoxides, phenolics, aminoplasts, saphorolactones, nucleosides, dendrimers, and combinations thereof.
60. The antioxidant coupled packaging material of claim 54, wherein the antioxidants are selected from the group consisting of ascorbic acid, vitamin E derivatives, tocol, α -tocopherol, β -tocopherol, γ -tocopherol, ϕ -tocopherol, ϵ -tocopherol, ξ 1-tocopherol, ξ 2-tocopherol, η -tocopherol, vitamin B derivatives, thiamine, cyanocobalamin, ergocalciferol, cholecalciferol, vitamin K derivatives, phytonadione, menaquinone, quercetin, vitamin A derivatives, retinol, retinal, 3,4-didehydroretinol, α -carotene, β -carotene, δ -carotene, γ -carotene, cryptoxanthin, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, tartaric acid, caffeic acid, diaryl amines, thioethers, quinones, porphyrins, phenolphthalein, indophenol, coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof.
61. The antioxidant coupled packaging material of claim 54, wherein the monomeric units are biodegradable monomers.
62. The antioxidant coupled packaging material of claim 61, wherein the biodegradable monomers are selected from the group consisting of polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids, "pseudo" amino acids, esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, biodegradable dendrimers, and combinations thereof.
63. The antioxidant coupled packaging material of claim 54, wherein an enzyme functionalizes the monomeric units with antioxidants.

64. The antioxidant coupled packaging material of claim 63, wherein the enzyme is selected from the group comprising proteases, glycosidases, and lipases.
- 5 65. The antioxidant coupled packaging material of claim 54, wherein an enzyme polymerizes the monomeric units.
66. The antioxidant coupled packaging material of claim 65, wherein the enzyme is horseradish peroxidase (HRP).
- 10 67. A controlled delivery system for antioxidants comprising
an antioxidant bound to a biodegradable polymer composed of biodegradable monomers, the biodegradable polymer formed by coupling the antioxidant to each of a plurality of biodegradable monomers to form antioxidant-coupled biodegradable monomers and enzymatically polymerizing the antioxidant-coupled biodegradable monomers, wherein the
15 antioxidant is present in an amount from about 20% to about 80% (w/w).
68. The controlled delivery system of claim 67, wherein the antioxidant is selected from the group consisting of ascorbic acid, vitamin E derivatives, tocol, α -tocopherol, β -tocopherol, γ -tocopherol, ϕ -tocopherol, ϵ -tocopherol, ξ 1'-tocopherol, ξ 2-tocopherol, η -tocopherol, vitamin B
20 derivatives, thiamine, cyanocobalamin, ergocalciferol, cholecalciferol, vitamin K derivatives, phytonadione, menaquinone, quercetin, vitamin A derivatives, retinol, retinal, 3,4-didehydroretinol, α -carotene, β -carotene, δ -carotene, γ -carotene, cryptoxanthin, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, alpha-lipoic acid, glutathione, carotenoids, allylic sulfides, selegiline, N-actylcysteine, lecithin, tartaric acid, caffeic acid, diaryl amines,
25 thioethers, quinones, tannins, xanthenes, procyanidins, porphrins, phenolphthalein, indophenol, coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof.
69. The controlled delivery system of claim 67, wherein the antioxidant is ascorbic acid.
- 30 70. The controlled delivery system of claim 67, wherein the biodegradable monomers are natural.

71. The controlled delivery system of claim 67, wherein the biodegradable monomers are synthetic.
- 5 72. The controlled delivery system of claim 67, wherein the biodegradable monomers are selected from the group consisting of polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids, "pseudo" amino acids, esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, biodegradable dendrimers, and combinations thereof.
- 10 73. The controlled delivery system of claim 67, wherein the antioxidant-coupled polymer is a homopolymer.
- 15 74. The controlled delivery system of claim 67, wherein the antioxidant-coupled polymer is a copolymer.
75. The controlled delivery system of claim 67, wherein the antioxidant-coupled polymer is selected from the group consisting of a film, a fiber, a coating, or combinations thereof.
- 20 76. The controlled delivery system of claim 67, wherein the antioxidant coupled polymer can be implanted into a subject.
77. The controlled delivery system of claim 67, wherein the antioxidant coupled polymer can be ingested by a subject.
- 25 78. The controlled delivery system of claim 67, wherein the antioxidant-coupled polymer comprises a topical ointment.
79. The controlled delivery system of claim 67, wherein the antioxidants are coupled to the biodegradable monomers using an enzyme.
- 30

80. The controlled delivery system of claim 79, wherein the enzyme is a lipase.
81. The controlled delivery system of claim 80, wherein the enzyme is *Candida antarctica* lipase.
- 5 82. The controlled delivery system of claim 67, wherein the biodegradable monomers are polymerized using an enzyme.
83. The controlled delivery system of claim 82, wherein the biodegradable monomers are
10 polymerized using the enzyme horseradish peroxidase (HRP).
84. A method of controlled delivery of an antioxidant to a subject comprising
coupling an antioxidant to each of a plurality of biodegradable monomers; and
enzymatically polymerizing the antioxidant-coupled biodegradable monomers;
15 whereby the resultant antioxidant coupled polymer will degrade over time and deliver the antioxidant at a controlled rate to a subject.
85. The method of claim 84, wherein the method further comprises coupling at least 70% of
the resultant polymer's monomer units with antioxidants.
- 20 86. The method of claim 84, wherein the method further comprises coupling at least 90% of the resultant polymer's monomer units with antioxidants.
87. The method of claim 84, wherein the method further comprises coupling at least one
25 antioxidant per monomer.
88. The method of claim 84, wherein the method further comprises selecting the antioxidant
from the group consisting of ascorbic acid, vitamin E derivatives, tocol, α -tocopherol, β -
tocopherol, γ -tocopherol, ϕ -tocopherol, ϵ -tocopherol, ξ 1-tocopherol, ξ 2-tocopherol, η -
30 tocopherol, vitamin B derivatives, thiamine, cyanocobalamin, ergocalciferol, cholecalciferol, vitamin K derivatives, phytonadione, menaquinone, quercetin, vitamin A derivatives, retinol,

retinal, 3,4-didehydroretinol, α -carotene, β -carotene, δ -carotene, γ -carotene, cryptoxanthin, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, alpha-lipoic acid, glutathione, carotenoids, allylic sulfides, selegiline, N-actylcysteine, lecithin, tartaric acid, caffeic acid, diaryl amines, thioethers, quinones, tannins, xanthenes, procyanidins, porphyrins, phenolphthalein, indophenol, coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof.

89. The method of claim 84, wherein the biodegradable monomers are selected from the group consisting of polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids, "pseudo" amino acids, esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, biodegradable dendrimers, and combinations thereof.

90. The method of claim 84, wherein the step of coupling an antioxidant to each of a plurality of biodegradable monomers further comprises utilizing an enzyme.

91. The method of claim 90, wherein the method further comprises selectively acylating a primary hydroxyl group of the antioxidant.

92. The method of claim 90, wherein the step of enzymatically coupling an antioxidant to each of a plurality of monomers further comprises utilizing a lipase.

93. The method of claim 92, wherein the step of enzymatically coupling an antioxidant to each of a plurality of monomers further comprises using the lipase *Candida antarctica* lipase.

94. The method of claim 84, wherein the step of polymerizing the antioxidant-coupled monomers further comprises using the enzyme horseradish peroxidase (HRP).

95. The method of claim 84, wherein the method further comprises casting the antioxidant-coupled polymer into a shaped form selected from the group consisting of a film, a fiber, a coating, a sheet, and combinations thereof.

96. The method of claim 84, wherein the method further comprises housing oxygen sensitive material in direct contact with the shaped form.
97. The method of claim 84, wherein the method further comprises coating a pharmaceutical agent with the antioxidant-coupled biodegradable polymer.
98. The method of claim 84, wherein the step of polymerizing the antioxidant-coupled monomers into an antioxidant-coupled polymer, further comprises forming a homopolymer.
99. The method of claim 84, wherein the step of polymerizing the antioxidant-coupled monomers into an antioxidant-coupled polymer, further comprises forming a copolymer.
100. The method of claim 84, wherein the method further comprises embedding a pharmaceutical agent within the antioxidant-coupled biodegradable polymer.
101. The method of claim 84, wherein the method further comprises casting the polymer around the material.
102. A topical ointment for controlled delivery of antioxidants comprising an antioxidant bound to a biodegradable polymer composed of biodegradable monomers, the biodegradable polymer formed by coupling the antioxidant to each of a plurality of biodegradable monomers to form antioxidant-coupled biodegradable monomers and enzymatically polymerizing the antioxidant-coupled biodegradable monomers, wherein the antioxidant is present in an amount from about 20% to about 80% (w/w).
103. The topical ointment of claim 102, wherein the biodegradable monomers are selected from the group consisting of polyesters, glycolides, lactides, trimethylene carbonates, caprolactones, dioxanone, hydroxybutyrates, hydroxyvalerates, carbonates, amino acids, "pseudo" amino acids, esteramides, anhydrides, orthoesters, saphorolactones, nucleosides, biodegradable dendrimers, and combinations thereof.

104. The topical ointment of claim 102, wherein the antioxidant is selected from the group consisting of ascorbic acid, vitamin E derivatives, tocol, α -tocopherol, β -tocopherol, γ -tocopherol, ϕ -tocopherol, ε -tocopherol, ξ 1-tocopherol, ξ 2-tocopherol, η -tocopherol, vitamin B derivatives, thiamine, cyanocobalamin, ergocalciferol, cholecalciferol, vitamin K derivatives,
5 phytonadione, menaquinone, quercetin, vitamin A derivatives, retinol, retinal, 3,4-didehydroretinol, α -carotene, β -carotene, δ -carotene, γ -carotene, cryptoxanthin, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, alpha-lipoic acid, glutathione, carotenoids, allylic sulfides, selegiline, N-actylcysteine, lecithin, tartaric acid, caffeic acid, diaryl amines, thioethers, quinones, tannins, xanthenes, procyanidins, porphrins, phenolphthalein, indophenol,
10 coumarins, flavones, flavanones, and isomers, derivatives, and combinations thereof.
105. The topical ointment of claim 102, wherein the ointment further comprises a pharmaceutically acceptable excipient.
- 15 106. The topical ointment of claim 102, wherein the ointment further comprises a cosmetically acceptable excipient.
107. The topical ointment of claim 102, wherein the antioxidants are coupled to biodegradable monomers using an enzyme.
20
108. The topical ointment of claim 107, wherein the enzyme is a lipase.
109. The topical ointment of claim 108, wherein the enzyme is *Candida antarctica* lipase.
- 25 110. The topical ointment of claim 102, wherein at least 10% of the resultant polymer's monomeric units are functionalized with antioxidants.
111. The topical ointment of claim 102, wherein at least 1% of the resultant polymer's monomeric units are functionalized with antioxidants.
30


112. The topical ointment of claim 102, wherein the topical ointment has at least one antioxidant per monomer.

113. The topical ointment of claim 102, wherein the polymer is polymerized using an enzyme.

5

114. The topical ointment of claim 113, wherein the polymer is polymerized using the enzyme horseradish peroxidase (HRP).

115. An ascorbyl coupled polymer with inherent antioxidant activity comprising
10 functionalized units of formula:



wherein Y is absent, C_2H_2O , C_7H_4O or a linking group;

Z is selected from the group consisting of O, S, N, C, CH_3 , C_6H_3 , C_6H_4 , C_aH_b , $C_6H_{10}O_2$, and $C_aH_bO_m$, wherein a, b, and m are integers;

15 R is selected from the group consisting of absent, hydrogen, oxygen, an alkyl, a hydroxy, an aryl, an aliphatic group, an aromatic group, an acyl group, an alkoxy group, an alkylene group, an alkenylene group, an alkynylene group, a hydroxycarbonylalkyl group, an anhydride, a halide, an amide, an amine, and a heterocyclic aromatic group; and

n is an integer greater than or equal to one, denoting the degree of polymerization.

20

116. The ascorbyl coupled polymer of claim 115, wherein at least 1% of the polymer comprises the functionalized units.

117. The ascorbyl coupled polymer of claim 115, wherein at least 10% of the polymer
25 comprises the functionalized units.

118. The ascorbyl coupled polymer of claim 115, wherein at least 50% of the polymer comprises the functionalized units.

Abstract of the Invention

Methods and compositions are disclosed for the preparation of free radical scavenging polymers and polymer films functionalized with antioxidants. Enzymatic and chemical tailoring of monomers with antioxidants followed by enzymatic polymerization is described. These antioxidant functionalized polymers can increase shelf life and quality of food products, as well as, increase effectiveness of pharmaceutical agents when used as packaging or as coatings on packaging for oxygen sensitive materials. The novel enzymatic covalent coupling of antioxidants to a polymer enhances the free radical scavenging ability of packaging while also inhibiting the escape of the antioxidants, and thus limiting exposure and/or absorption by an individual. In addition to its use in food or pharmaceutical packaging, methods are disclosed for using the antioxidant coupled polymers in a variety of applications including as coatings on the inside of medical devices, such as stents and catheters, which would substantially reduce free radical damage and/or oxygen depletion during medical procedures. Furthermore, through the coupling of antioxidants to biodegradable polymers, controlled delivery and sustained release of an antioxidant to a subject is possible.

20

25

1116277.1

6114-2364 / 11.2702

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7





Figure 8



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.